Ciprofloxacin	O
induces	O
an	O
immunomodulatory	O
stress	O
response	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Exposure	O
of	O
cells	O
to	O
adverse	O
environmental	O
conditions	O
invokes	O
a	O
genetically	O
programmed	O
series	O
of	O
events	O
resulting	O
in	O
the	O
induction	O
of	O
specific	B-DNA
genes	I-DNA
.	O

The	O
fluoroquinolone	O
antibiotic	O
ciprofloxacin	O
has	O
recently	O
been	O
reported	O
to	O
upregulate	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
gene	O
induction	O
.	O

In	O
the	O
present	O
investigation	O
,	O
the	O
effect	O
of	O
ciprofloxacin	O
at	O
supratherapeutic	O
concentrations	O
on	O
immediate-early	O
(	O
<	O
2	O
h	O
)	O
gene	O
expression	O
in	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
was	O
studied	O
with	O
Northern	O
blots	O
.	O

In	O
addition	O
,	O
transcriptional	O
activity	O
of	O
IL-2	B-protein
and	O
metallothionein	B-DNA
enhancer	I-DNA
and	I-DNA
promoter	I-DNA
regions	I-DNA
and	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
,	O
NF-kappaB	B-protein
,	O
and	O
NF-AT	B-protein
were	O
analyzed	O
by	O
chloramphenicol	B-protein
acetyltransferase	I-protein
(	O
CAT	B-protein
)	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
respectively	O
.	O

The	O
concentration	O
of	O
c-fos	B-RNA
,	I-RNA
c-jun	I-RNA
,	I-RNA
c-myc	I-RNA
,	I-RNA
junB	I-RNA
,	I-RNA
and	I-RNA
fra-1	I-RNA
mRNAs	I-RNA
was	O
increased	O
in	O
activated	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
incubated	O
with	O
ciprofloxacin	O
compared	O
to	O
that	O
in	O
untreated	O
controls	O
.	O

Ciprofloxacin	O
increased	O
CAT	B-protein
activity	O
in	O
stimulated	O
lymphocytes	O
transfected	O
with	O
plasmids	B-cell_type
containing	O
either	O
the	O
IL-2	B-protein
or	O
metallothionein	B-DNA
enhancer	I-DNA
.	O

Furthermore	O
,	O
among	O
the	O
transcription	B-protein
factors	I-protein
tested	O
,	O
AP-1	B-protein
activity	O
was	O
increased	O
in	O
stimulated	B-cell_type
purified	I-cell_type
T	I-cell_type
helper	I-cell_type
lymphocytes	I-cell_type
incubated	O
with	O
ciprofloxacin	O
compared	O
to	O
drug-free	B-cell_type
controls	I-cell_type
.	O

Taken	O
together	O
,	O
ciprofloxacin	O
increased	O
the	O
levels	O
of	O
immediate-early	B-RNA
transcripts	I-RNA
,	O
enhanced	O
IL-2	B-protein
and	O
metallothionein	B-protein
promoter	O
induction	O
,	O
and	O
upregulated	O
AP-1	B-protein
concentrations	O
in	O
primary	B-cell_type
lymphocytes	I-cell_type
,	O
reflecting	O
a	O
program	O
commonly	O
observed	O
in	O
mammalian	O
stress	O
responses	O
.	O

ANTIMICROBIAL	NULL
AGENTS	NULL
AND	NULL
CHEMOTHERAPY	NULL
,	NULL
Aug.	NULL
1998	NULL
,	NULL
p.	NULL
1923-1930	NULL
0066-4804/98/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

42	NULL
,	NULL
No	NULL
.	NULL

8	NULL
Copyright	NULL
©	NULL
1998	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Ciprofloxacin	NULL
Induces	NULL
an	NULL
Immunomodulatory	NULL
Stress	NULL
Response	NULL
in	NULL
Human	NULL
T	NULL
Lymphocytes	NULL
KRISTIAN	NULL
RIESBECK	NULL
,	NULL
*	NULL
ARNE	NULL
FORSGREN	NULL
,	NULL
AGNETHE	NULL
HENRIKSSON	NULL
,	NULL
AND	NULL
ANDERS	NULL
BREDBERG	NULL
Department	NULL
of	NULL
Medical	NULL
Microbiology	NULL
,	NULL
Lund	NULL
University	NULL
,	NULL
Malmi	NULL
University	NULL
Hospital	NULL
,	NULL
$	NULL
-205	NULL
02	NULL
Malm6	NULL
,	NULL
Sweden	NULL
Received	NULL
9	NULL
February	NULL
1998/Returned	NULL
for	NULL
modification	NULL
13	NULL
May	NULL
1998/Accepted	NULL
3	NULL
June	NULL
1998	NULL
Exposure	NULL
of	NULL
cells	NULL
to	NULL
adverse	NULL
environmental	NULL
conditions	NULL
invokes	NULL
a	NULL
genetically	NULL
programmed	NULL
series	NULL
of	NULL
events	NULL
resulting	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
specific	NULL
genes	NULL
.	NULL

The	NULL
fluoroquinolone	NULL
antibiotic	NULL
ciprofloxacin	NULL
has	NULL
recently	NULL
been	NULL
reported	NULL
to	NULL
upregulate	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
gene	NULL
induction	NULL
.	NULL

In	NULL
the	NULL
present	NULL
investigation	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
ciprofloxacin	NULL
at	NULL
supratherapeutic	NULL
concentrations	NULL
on	NULL
immediate-early	NULL
(	NULL
<	NULL
2	NULL
h	NULL
)	NULL
gene	NULL
expression	NULL
in	NULL
primary	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
was	NULL
studied	NULL
with	NULL
Northern	NULL
blots	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
transcriptional	NULL
activity	NULL
of	NULL
IL-2	NULL
and	NULL
metallothionein	NULL
enhancer	NULL
and	NULL
promoter	NULL
regions	NULL
and	NULL
transcription	NULL
factors	NULL
AP-1	NULL
,	NULL
NF-KB	NULL
,	NULL
and	NULL
NF-AT	NULL
were	NULL
analyzed	NULL
by	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
c-myc	NULL
,	NULL
junB	NULL
,	NULL
and	NULL
fra-1	NULL
mRNAs	NULL
was	NULL
increased	NULL
in	NULL
activated	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
untreated	NULL
controls	NULL
.	NULL

Ciprofloxacin	NULL
increased	NULL
CAT	NULL
activity	NULL
in	NULL
stimulated	NULL
lymphocytes	NULL
transfected	NULL
with	NULL
plasmids	NULL
containing	NULL
either	NULL
the	NULL
IL-2	NULL
or	NULL
metallothionein	NULL
enhancer	NULL
.	NULL

Furthermore	NULL
,	NULL
among	NULL
the	NULL
transcription	NULL
factors	NULL
tested	NULL
,	NULL
AP-1	NULL
activity	NULL
was	NULL
increased	NULL
in	NULL
stimulated	NULL
purified	NULL
T	NULL
helper	NULL
lymphocytes	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
compared	NULL
to	NULL
drug-free	NULL
controls	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
ciprofloxacin	NULL
increased	NULL
the	NULL
levels	NULL
of	NULL
immediate-early	NULL
transcripts	NULL
,	NULL
enhanced	NULL
IL-2	NULL
and	NULL
metallothionein	NULL
promoter	NULL
induction	NULL
,	NULL
and	NULL
upregulated	NULL
AP-1	NULL
concentrations	NULL
in	NULL
primary	NULL
lymphocytes	NULL
,	NULL
reflecting	NULL
a	NULL
program	NULL
commonly	NULL
observed	NULL
in	NULL
mammalian	NULL
stress	NULL
responses	NULL
.	NULL

Fluoroquinolones	NULL
,	NULL
which	NULL
perform	NULL
their	NULL
bactericidal	NULL
effect	NULL
by	NULL
inhibiting	NULL
DNA	NULL
gyrase	NULL
(	NULL
a	NULL
type	NULL
II	NULL
topoisomerase	NULL
)	NULL
(	NULL
5	NULL
)	NULL
,	NULL
are	NULL
known	NULL
to	NULL
interfere	NULL
with	NULL
certain	NULL
immune	NULL
functions	NULL
.	NULL

Ciprofloxacin	NULL
and	NULL
other	NULL
quinolones	NULL
at	NULL
>	NULL
20	NULL
g/ml	NULL
inhibit	NULL
peripheral	NULL
blood	NULL
lymphocyte	NULL
(	NULL
PBL	NULL
)	NULL
cell	NULL
growth	NULL
by	NULL
30	NULL
to	NULL
35	NULL
%	NULL
,	NULL
causing	NULL
impaired	NULL
cell	NULL
cycle	NULL
progression	NULL
through	NULL
the	NULL
S	NULL
phase	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Cell	NULL
cycle	NULL
analysis	NULL
thus	NULL
indicates	NULL
DNA	NULL
synthesis	NULL
to	NULL
be	NULL
inhibited	NULL
by	NULL
fluoroquinolones	NULL
at	NULL
these	NULL
concentrations	NULL
.	NULL

Despite	NULL
this	NULL
adverse	NULL
effect	NULL
on	NULL
cell	NULL
growth	NULL
,	NULL
fluoroquinolone	NULL
antibiotics	NULL
at	NULL
therapeutic	NULL
concentrations	NULL
(	NULL
between	NULL
1.56	NULL
and	NULL
6.25	NULL
mg/ml	NULL
!	NULL
)	NULL

are	NULL
able	NULL
to	NULL
enhance	NULL
[	NULL
°HJthymidine	NULL
incorporation	NULL
two-	NULL
to	NULL
threefold	NULL
in	NULL
phytohemag-glutinin	NULL
(	NULL
PHA	NULL
)	NULL
-stimulated	NULL
PBLs	NULL
,	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
control	NULL
cells	NULL
unexposed	NULL
to	NULL
antibiotics	NULL
,	NULL
the	NULL
effects	NULL
being	NULL
most	NULL
pronounced	NULL
after	NULL
4	NULL
to	NULL
5	NULL
days	NULL
of	NULL
lymphocyte	NULL
incubation	NULL
(	NULL
8	NULL
,	NULL
38	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
stimulatory	NULL
effects	NULL
on	NULL
thymidine	NULL
incorpo-ration	NULL
,	NULL
ciprofloxacin	NULL
(	NULL
range	NULL
,	NULL
5	NULL
to	NULL
80	NULL
ug/ml	NULL
)	NULL
and	NULL
other	NULL
fluoroquinolones	NULL
potentiate	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
synthesis	NULL
by	NULL
PHA-stimulated	NULL
PBLs	NULL
(	NULL
26	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Experiments	NULL
with	NULL
the	NULL
human	NULL
T-cell	NULL
lymphoma	NULL
cell	NULL
line	NULL
Jurkat	NULL
and	NULL
the	NULL
murine	NULL
equivalent	NULL
EL-4	NULL
,	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
IL-2	NULL
promoter	NULL
region	NULL
,	NULL
show	NULL
that	NULL
ciprofloxacin	NULL
enhances	NULL
IL-2	NULL
promoter	NULL
activation	NULL
(	NULL
27	NULL
,	NULL
30	NULL
)	NULL
.	NULL

An	NULL
earlier	NULL
and	NULL
stronger	NULL
ciprofioxacin-de-pendent	NULL
activation	NULL
of	NULL
the	NULL
transcriptional	NULL
regulation	NULL
factors	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
1	NULL
(	NULL
NF-AT-1	NULL
)	NULL
and	NULL
activator	NULL
protein	NULL
1	NULL
(	NULL
AP-1	NULL
)	NULL
is	NULL
observed	NULL
in	NULL
these	NULL
immortalized	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
accordance	NULL
with	NULL
these	NULL
findings	NULL
,	NULL
under	NULL
certain	NULL
in	NULL
vitro	NULL
condi-tions	NULL
,	NULL
ciprofloxacin	NULL
(	NULL
20	NULL
to	NULL
80	NULL
pg/ml	NULL
)	NULL
counteracts	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
immunosuppressive	NULL
agent	NULL
cyclosporine	NULL
A	NULL
that	NULL
normally	NULL
inhibits	NULL
the	NULL
phosphatase	NULL
activity	NULL
of	NULL
calcineurin	NULL
,	NULL
causing	NULL
impaired	NULL
NF-AT-1	NULL
activity	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Ciprofloxacin	NULL
thus	NULL
interferes	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Medical	NULL
Microbiology	NULL
,	NULL
Lund	NULL
University	NULL
,	NULL
Malméd	NULL
University	NULL
Hospital	NULL
,	NULL
S-205	NULL
02	NULL
Malmé	NULL
,	NULL
Sweden	NULL
.	NULL

Phone	NULL
:	NULL
46-40-331340	NULL
.	NULL

Fax	NULL
:	NULL
46-40-336234	NULL
.	NULL

E-mail	NULL
:	NULL
kristian.riesbeck	NULL
@	NULL
mikrobiol.mas.lu.se	NULL
.	NULL

1923	NULL
with	NULL
a	NULL
regulative	NULL
pathway	NULL
common	NULL
to	NULL
several	NULL
cytokines	NULL
.	NULL

In-deed	NULL
,	NULL
analysis	NULL
of	NULL
cytokine	NULL
mRNAs	NULL
in	NULL
ciprofloxacin	NULL
(	NULL
20	NULL
to	NULL
80	NULL
g/ml	NULL
)	NULL
-treated	NULL
PBLs	NULL
revealed	NULL
that	NULL
not	NULL
only	NULL
IL-2	NULL
mRNA	NULL
is	NULL
enhanced	NULL
but	NULL
so	NULL
are	NULL
an	NULL
array	NULL
of	NULL
other	NULL
cytokine	NULL
mRNAs	NULL
,	NULL
including	NULL
gamma	NULL
interferon	NULL
(	NULL
IFN-y	NULL
)	NULL
and	NULL
IL-4	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
there	NULL
are	NULL
several	NULL
reports	NULL
on	NULL
ciprofloxacin-dependent	NULL
immunomodu-lation	NULL
in	NULL
vivo	NULL
,	NULL
strongly	NULL
indicating	NULL
that	NULL
the	NULL
cytokine	NULL
upregulation	NULL
observed	NULL
is	NULL
not	NULL
an	NULL
in	NULL
vitro	NULL
artifact	NULL
(	NULL
19	NULL
,	NULL
36	NULL
,	NULL
38	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Exposure	NULL
of	NULL
cells	NULL
to	NULL
DNA-damaging	NULL
agents	NULL
induces	NULL
numerous	NULL
genes	NULL
that	NULL
facilitate	NULL
the	NULL
repair	NULL
of	NULL
such	NULL
lesions	NULL
.	NULL

This	NULL
response	NULL
is	NULL
essential	NULL
for	NULL
an	NULL
organism	NULL
to	NULL
adapt	NULL
to	NULL
life-threatening	NULL
environmental	NULL
conditions	NULL
and	NULL
to	NULL
duplicate	NULL
its	NULL
genetic	NULL
material	NULL
with	NULL
the	NULL
highest	NULL
fidelity	NULL
.	NULL

This	NULL
sensory	NULL
network	NULL
has	NULL
been	NULL
thoroughly	NULL
characterized	NULL
in	NULL
bacteria	NULL
.	NULL

Treatment	NULL
of	NULL
Escherichia	NULL
coli	NULL
with	NULL
agents	NULL
that	NULL
damage	NULL
DNA	NULL
or	NULL
inhibit	NULL
replication	NULL
(	NULL
for	NULL
example	NULL
,	NULL
quinolone	NULL
antibacterials	NULL
)	NULL
induces	NULL
a	NULL
set	NULL
of	NULL
physiological	NULL
responses	NULL
that	NULL
have	NULL
collectively	NULL
been	NULL
called	NULL
the	NULL
SOS	NULL
response	NULL
(	NULL
40	NULL
)	NULL
.	NULL

These	NULL
responses	NULL
promote	NULL
cell	NULL
survival	NULL
,	NULL
and	NULL
blocking	NULL
them	NULL
genetically	NULL
leads	NULL
to	NULL
DNA	NULL
damage	NULL
sensitivity	NULL
.	NULL

Numerous	NULL
genes	NULL
that	NULL
are	NULL
transcriptionally	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
DNA	NULL
damage	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
including	NULL
several	NULL
involved	NULL
in	NULL
excision	NULL
repair	NULL
,	NULL
recombinational	NULL
repair	NULL
,	NULL
SOS	NULL
repression	NULL
,	NULL
mutagenesis	NULL
,	NULL
and	NULL
cell	NULL
cycle	NULL
arrest	NULL
.	NULL

In	NULL
eukaryotic	NULL
cells	NULL
,	NULL
a	NULL
network	NULL
of	NULL
overlapping	NULL
systems	NULL
seems	NULL
to	NULL
be	NULL
activated	NULL
following	NULL
exposure	NULL
to	NULL
DNA-damaging	NULL
agents	NULL
.	NULL

Many	NULL
genes	NULL
are	NULL
induced	NULL
specifically	NULL
by	NULL
UV	NULL
and	NULL
gamma	NULL
rays	NULL
,	NULL
while	NULL
others	NULL
also	NULL
respond	NULL
to	NULL
alkylating	NULL
agents	NULL
and	NULL
to	NULL
growth	NULL
arrest	NULL
(	NULL
7	NULL
,	NULL
10	NULL
,	NULL
17	NULL
)	NULL
.	NULL

In	NULL
several	NULL
cases	NULL
,	NULL
the	NULL
cellular	NULL
response	NULL
to	NULL
genotoxic	NULL
treatment	NULL
is	NULL
triggered	NULL
by	NULL
signal	NULL
transduction	NULL
pathways	NULL
which	NULL
are	NULL
not	NULL
DNA	NULL
damage	NULL
specific	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
many	NULL
of	NULL
the	NULL
genes	NULL
triggered	NULL
by	NULL
DNA	NULL
damage	NULL
are	NULL
also	NULL
induced	NULL
by	NULL
agents	NULL
such	NULL
as	NULL
phorbol	NULL
esters	NULL
and	NULL
by	NULL
metabolic	NULL
or	NULL
oxidative	NULL
stress	NULL
)	NULL
(	NULL
5	NULL
,	NULL
10	NULL
,	NULL
11	NULL
,	NULL
34	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
primary	NULL
stress-inducible	NULL
genes	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
the	NULL
immediate-early	NULL
expressed	NULL
genes	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
and	NULL
c-myc	NULL
)	NULL
is	NULL
rapid	NULL
and	NULL
independent	NULL
of	NULL
protein	NULL
synthesis	NULL
,	NULL
whereas	NULL
1924	NULL
RIESBECK	NULL
ET	NULL
AL	NULL
.	NULL

secondary	NULL
induced	NULL
genes	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
early	NULL
expressed	NULL
cytokines	NULL
and	NULL
genes	NULL
involved	NULL
in	NULL
DNA	NULL
repair	NULL
)	NULL
are	NULL
expressed	NULL
later	NULL
and	NULL
are	NULL
dependent	NULL
on	NULL
the	NULL
primary	NULL
ones	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

The	NULL
eukaryotic	NULL
UV	NULL
response	NULL
is	NULL
the	NULL
most	NULL
well-characterized	NULL
stress-induced	NULL
pathway	NULL
and	NULL
resembles	NULL
in	NULL
many	NULL
ways	NULL
the	NULL
bacterial	NULL
SOS	NULL
response	NULL
(	NULL
7	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Following	NULL
UV	NULL
exposure	NULL
,	NULL
the	NULL
mem-brane-associated	NULL
Sre	NULL
tyrosine	NULL
kinases	NULL
are	NULL
induced	NULL
,	NULL
leading	NULL
to	NULL
activation	NULL
of	NULL
cytoplasmic	NULL
protein	NULL
kinases	NULL
that	NULL
eventually	NULL
increase	NULL
AP-1	NULL
activity	NULL
and	NULL
induce	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-kB	NULL
.	NULL

The	NULL
enhancement	NULL
in	NULL
AP-1	NULL
activity	NULL
is	NULL
mediated	NULL
both	NULL
by	NULL
induction	NULL
of	NULL
c-jun	NULL
and	NULL
c-fos	NULL
expression	NULL
and	NULL
by	NULL
posttranslational	NULL
modification	NULL
of	NULL
c-Jun	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
genes	NULL
identified	NULL
during	NULL
a	NULL
UV	NULL
response	NULL
are	NULL
not	NULL
specifically	NULL
linked	NULL
to	NULL
DNA	NULL
repair	NULL
.	NULL

However	NULL
,	NULL
the	NULL
gene	NULL
product	NULL
of	NULL
the	NULL
UV-	NULL
and	NULL
gamma-ray-induc-ible	NULL
GADD45	NULL
gene	NULL
stimulates	NULL
excision	NULL
repair	NULL
as	NULL
well	NULL
as	NULL
inhibits	NULL
DNA	NULL
replication	NULL
by	NULL
blocking	NULL
the	NULL
cell	NULL
cycle	NULL
at	NULL
the	NULL
G	NULL
,	NULL
checkpoint	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
37	NULL
)	NULL
.	NULL

Metallothionein	NULL
is	NULL
another	NULL
well-studied	NULL
example	NULL
of	NULL
a	NULL
UV	NULL
and	NULL
DNA	NULL
damage-induc-ible	NULL
gene	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Overexpression	NULL
of	NULL
metallothionein	NULL
protects	NULL
mammalian	NULL
cells	NULL
against	NULL
oxidative	NULL
stress	NULL
and	NULL
can	NULL
dramatically	NULL
reduce	NULL
the	NULL
level	NULL
of	NULL
intracellular	NULL
oxygen	NULL
radicals	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Topoisomerase	NULL
II	NULL
inhibitors	NULL
have	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
trigger	NULL
DNA	NULL
damage	NULL
responses	NULL
(	NULL
20	NULL
,	NULL
23	NULL
,	NULL
31	NULL
,	NULL
39	NULL
)	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
that	NULL
ciprofloxacin	NULL
at	NULL
high	NULL
concentrations	NULL
(	NULL
80	NULL
pg/ml	NULL
)	NULL
interferes	NULL
with	NULL
topoisomerase	NULL
II	NULL
in	NULL
human	NULL
lymphoblastoid	NULL
Raji	NULL
cells	NULL
(	NULL
2	NULL
)	NULL
.	NULL

This	NULL
phenomenon	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
IL-2	NULL
and	NULL
other	NULL
cytokines	NULL
are	NULL
enhanced	NULL
in	NULL
ciprofloxacin-treated	NULL
cells	NULL
(	NULL
26	NULL
,	NULL
30	NULL
)	NULL
,	NULL
led	NULL
us	NULL
to	NULL
examine	NULL
whether	NULL
ciprofloxacin	NULL
induces	NULL
a	NULL
stress	NULL
response	NULL
in	NULL
primary	NULL
human	NULL
lymphoid	NULL
cells	NULL
.	NULL

Surprisingly	NULL
,	NULL
ciprofloxacin	NULL
superinduced	NULL
both	NULL
IL-2	NULL
and	NULL
metallothionein	NULL
gene	NULL
induction	NULL
in	NULL
PHA-activated	NULL
PBLs	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
untreated	NULL
controls	NULL
.	NULL

Ciprofloxacin	NULL
was	NULL
also	NULL
found	NULL
to	NULL
increase	NULL
the	NULL
concentrations	NULL
of	NULL
immediate-early	NULL
gene	NULL
transcripts	NULL
without	NULL
influencing	NULL
mRNA	NULL
stability	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
was	NULL
strongly	NULL
induced	NULL
by	NULL
ciprofloxacin	NULL
,	NULL
whereas	NULL
binding	NULL
of	NULL
NF-AT-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
unaffected	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
increased	NULL
cytokine	NULL
production	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ciprofloxacin	NULL
is	NULL
most	NULL
likely	NULL
related	NULL
to	NULL
a	NULL
mammalian	NULL
stress	NULL
response	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents	NULL
.	NULL

Preservative-free	NULL
ciprofloxacin	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Bayer	NULL
(	NULL
Wup-pertal	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

PHA	NULL
(	NULL
Wellcome	NULL
,	NULL
Dartford	NULL
,	NULL
England	NULL
)	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
;	NULL
Sigma	NULL
,	NULL
Stockholm	NULL
,	NULL
Sweden	NULL
)	NULL
were	NULL
dissolved	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
and	NULL
dimethylsulfoxide	NULL
,	NULL
respectively	NULL
.	NULL

Actinomycin	NULL
D	NULL
was	NULL
purchased	NULL
from	NULL
Boehringer	NULL
Mannheim	NULL
(	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
10	NULL
pg/ml	NULL
.	NULL

Cells	NULL
.	NULL

Human	NULL
PBLs	NULL
were	NULL
isolated	NULL
from	NULL
buffy	NULL
coats	NULL
with	NULL
citrate	NULL
or	NULL
from	NULL
hep-arinized	NULL
blood	NULL
from	NULL
healthy	NULL
donors	NULL
by	NULL
centrifugation	NULL
on	NULL
a	NULL
step	NULL
gradient	NULL
of	NULL
Ficoll-Isopaque	NULL
(	NULL
Lymphoprep	NULL
;	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
(	NULL
26	NULL
)	NULL
.	NULL

PBLs	NULL
(	NULL
10	NULL
%	NULL
ml	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
humidified	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
atmosphere	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
HEPES	NULL
buffer	NULL
(	NULL
Gibco	NULL
,	NULL
Paisley	NULL
,	NULL
Scotland	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
glutamine	NULL
,	NULL
and	NULL
gentamicin	NULL
(	NULL
12	NULL
pg/ml	NULL
)	NULL
.	NULL

A	NULL
pure	NULL
population	NULL
(	NULL
>	NULL
98	NULL
%	NULL
)	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
was	NULL
isolated	NULL
with	NULL
Dynabeads	NULL
(	NULL
Dynal	NULL
,	NULL
Oslo	NULL
,	NULL
Norway	NULL
)	NULL
.	NULL

A	NULL
protocol	NULL
consisting	NULL
of	NULL
a	NULL
negative	NULL
selection	NULL
procedure	NULL
was	NULL
used	NULL
based	NULL
upon	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
biological	NULL
activity	NULL
of	NULL
IL-2	NULL
in	NULL
supernatants	NULL
was	NULL
analyzed	NULL
by	NULL
means	NULL
of	NULL
IL-2-dependent	NULL
stimulation	NULL
of	NULL
proliferation	NULL
of	NULL
the	NULL
murine	NULL
cytolytic	NULL
T-lymphocyte	NULL
line	NULL
CTLL-2	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
26	NULL
)	NULL
.	NULL

RNA	NULL
isolation	NULL
,	NULL
Northern	NULL
blots	NULL
,	NULL
and	NULL
DNA	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
prepared	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
30	NULL
)	NULL
.	NULL

RNA	NULL
(	NULL
10	NULL
to	NULL
20	NULL
pg	NULL
)	NULL
was	NULL
loaded	NULL
onto	NULL
formaldehyde-agarose	NULL
gels	NULL
and	NULL
blotted	NULL
to	NULL
nylon	NULL
filters	NULL
(	NULL
Hybond-N*	NULL
;	NULL
Amersham	NULL
,	NULL
Buckinghamshire	NULL
,	NULL
England	NULL
)	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Filters	NULL
were	NULL
hybridized	NULL
according	NULL
to	NULL
standard	NULL
protocols	NULL
and	NULL
exposed	NULL
for	NULL
24	NULL
to	NULL
72	NULL
h	NULL
to	NULL
preflashed	NULL
X-ray	NULL
film	NULL
(	NULL
XAR-5	NULL
;	NULL
Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
N.Y.	NULL
)	NULL
at	NULL
-70°C	NULL
by	NULL
using	NULL
intensifying	NULL
screens	NULL
.	NULL

Autoradio-graphs	NULL
were	NULL
quantified	NULL
by	NULL
scanning	NULL
laser	NULL
densitometry	NULL
.	NULL

The	NULL
gene-specific	NULL
probes	NULL
used	NULL
to	NULL
probe	NULL
RNA	NULL
blots	NULL
were	NULL
isolated	NULL
from	NULL
agarose	NULL
gels	NULL
after	NULL
digestion	NULL
of	NULL
the	NULL
plasmids	NULL
in	NULL
which	NULL
they	NULL
were	NULL
propagated	NULL
with	NULL
the	NULL
appropriate	NULL
restriction	NULL
endo-nucleases	NULL
.	NULL

The	NULL
c-myc	NULL
probe	NULL
was	NULL
a	NULL
1,000-bp	NULL
CleI-EcoRI	NULL
fragment	NULL
isolated	NULL
from	NULL
a	NULL
human	NULL
c-myc	NULL
cDNA	NULL
.	NULL

The	NULL
fre-	NULL
]	NULL
cDNA	NULL
was	NULL
a	NULL
900-bp	NULL
EcoRI	NULL
fragment	NULL
from	NULL
pfral	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
c-fos	NULL
probe	NULL
was	NULL
a	NULL
900-bp	NULL
Scal-Neo	NULL
!	NULL

fragment	NULL
from	NULL
pe-fos-1	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
)	NULL
,	NULL
and	NULL
the	NULL
c-jun	NULL
probe	NULL
was	NULL
an	NULL
~1,400-bp	NULL
NofL-HindIII	NULL
ANTIMICROB	NULL
.	NULL

AGENTS	NULL
CHEMOTHER	NULL
.	NULL

fragment	NULL
from	NULL
pRSV-cgun	NULL
(	NULL
provided	NULL
by	NULL
Michael	NULL
Karin	NULL
)	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
junB	NULL
probe	NULL
(	NULL
murine	NULL
)	NULL
was	NULL
a	NULL
1,800-bp	NULL
EcoRI	NULL
fragment	NULL
from	NULL
pjunB	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
fra-1	NULL
,	NULL
junB	NULL
,	NULL
and	NULL
c-myc	NULL
cDNAs	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
T.	NULL
Lindsten	NULL
.	NULL

The	NULL
IL-2-	NULL
and	NULL
IFN-y-specific	NULL
probes	NULL
and	NULL
B-actin	NULL
cDNA	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

DNA	NULL
fragments	NULL
were	NULL
labeled	NULL
with	NULL
[	NULL
«	NULL
-	NULL
``	NULL
°P	NULL
]	NULL
dCTP	NULL
(	NULL
specific	NULL
activity	NULL
3,000	NULL
Ci/mmol	NULL
;	NULL
PB	NULL
10205	NULL
;	NULL
Am-ersham	NULL
)	NULL
by	NULL
random	NULL
priming	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Free	NULL
nucleotides	NULL
were	NULL
separated	NULL
on	NULL
spin	NULL
columns	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

containing	NULL
Sephadex	NULL
G-50	NULL
fine	NULL
(	NULL
Phar-macia	NULL
)	NULL
.	NULL

For	NULL
transfection	NULL
experiments	NULL
,	NULL
expression	NULL
vectors	NULL
MT-CAT-SV	NULL
and	NULL
SV-IL-2-CAT	NULL
were	NULL
used	NULL
(	NULL
reference	NULL
30	NULL
and	NULL
references	NULL
therein	NULL
}	NULL
.	NULL

DNA	NULL
concentrations	NULL
were	NULL
estimated	NULL
by	NULL
DNA	NULL
dipstick	NULL
(	NULL
Invitrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
or	NULL
by	NULL
examination	NULL
on	NULL
agarose	NULL
gels	NULL
.	NULL

Transfections	NULL
and	NULL
CAT	NULL
assay	NULL
.	NULL

PBLs	NULL
were	NULL
stimulated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PHA	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
18	NULL
h	NULL
before	NULL
transfection	NULL
by	NULL
electroporation	NULL
with	NULL
a	NULL
Gene	NULL
Pulser	NULL
apparatus	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Before	NULL
transfection	NULL
,	NULL
cells	NULL
in	NULL
log	NULL
phase	NULL
were	NULL
washed	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
.	NULL

For	NULL
each	NULL
electroporation	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
350	NULL
pl	NULL
of	NULL
serum-free	NULL
medium	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
1-ml	NULL
electroporation	NULL
cuvette	NULL
with	NULL
a	NULL
0.4-cm	NULL
space	NULL
between	NULL
the	NULL
electrodes	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
10	NULL
jg	NULL
of	NULL
the	NULL
appropriate	NULL
plasmid	NULL
DNA	NULL
,	NULL
the	NULL
samples	NULL
were	NULL
gently	NULL
shaken	NULL
and	NULL
kept	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
5	NULL
min	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
subjected	NULL
to	NULL
electroporation	NULL
at	NULL
960	NULL
wF	NULL
and	NULL
450	NULL
V.	NULL
The	NULL
pulse	NULL
generated	NULL
an	NULL
exponential	NULL
decay	NULL
pulse	NULL
with	NULL
time	NULL
constants	NULL
at	NULL
36	NULL
to	NULL
43	NULL
ms	NULL
.	NULL

In	NULL
all	NULL
experiments	NULL
,	NULL
cells	NULL
were	NULL
mixed	NULL
after	NULL
the	NULL
transfections	NULL
and	NULL
aliquoted	NULL
to	NULL
different	NULL
culture	NULL
flasks	NULL
.	NULL

Cells	NULL
were	NULL
rested	NULL
for	NULL
36	NULL
h	NULL
followed	NULL
by	NULL
addition	NULL
of	NULL
ciprofloxacin	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
PHA	NULL
per	NULL
ml	NULL
.	NULL

After	NULL
activation	NULL
for	NULL
15	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
,	NULL
extracts	NULL
were	NULL
prepared	NULL
,	NULL
and	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
reaction	NULL
,	NULL
including	NULL
separation	NULL
of	NULL
products	NULL
by	NULL
thin-layer	NULL
chromatography	NULL
,	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
30	NULL
)	NULL
.	NULL

No	NULL
CAT	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
untransfected	NULL
cells	NULL
with	NULL
or	NULL
without	NULL
ciprofloxacin	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

Whole-cell	NULL
protein	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
33	NULL
)	NULL
,	NULL
and	NULL
protein	NULL
concentrations	NULL
were	NULL
determined	NULL
with	NULL
a	NULL
commercial	NULL
protein	NULL
assay	NULL
(	NULL
Pierce	NULL
bicinchoninic	NULL
acid	NULL
reagent	NULL
;	NULL
Tecator	NULL
,	NULL
Sollentuna	NULL
,	NULL
Sweden	NULL
)	NULL
.	NULL

Protein	NULL
extract	NULL
(	NULL
3.5	NULL
to	NULL
5.0	NULL
pg/reaction	NULL
)	NULL
was	NULL
mixed	NULL
with	NULL
1.0	NULL
pg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
and	NULL
5	NULL
%	NULL
binding	NULL
buffer	NULL
(	NULL
100	NULL
mM	NULL
phosphate	NULL
buffer	NULL
[	NULL
pH	NULL
6.0	NULL
]	NULL
,	NULL
50	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
10	NULL
mM	NULL
dithio-threitol	NULL
,	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
0.5	NULL
M	NULL
NaCl	NULL
,	NULL
500	NULL
ug	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
per	NULL
ml	NULL
,	NULL
20	NULL
%	NULL
Ficoll	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
15	NULL
l.	NULL
After	NULL
incubation	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
a	NULL
10,000-	NULL
or	NULL
15,000-cpm	NULL
*°P-kinased	NULL
probe	NULL
(	NULL
60	NULL
x	NULL
10~	NULL
``	NULL
to	NULL
90	NULL
x	NULL
107	NULL
``	NULL
pg	NULL
)	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
reaction	NULL
mixtures	NULL
were	NULL
incubated	NULL
for	NULL
a	NULL
further	NULL
20	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

Samples	NULL
were	NULL
separated	NULL
by	NULL
5	NULL
%	NULL
Tris-borate-EDTA-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
PAGE	NULL
)	NULL
were	NULL
fixed	NULL
,	NULL
dried	NULL
,	NULL
and	NULL
autoradiographed	NULL
.	NULL

The	NULL
probes	NULL
used	NULL
were	NULL
the	NULL
AP-1	NULL
consensus	NULL
binding	NULL
site	NULL
(	NULL
5'-ctagtgatgagtcagecggatc-3	NULL
'	NULL
)	NULL
,	NULL
an	NULL
Oct-1	NULL
binding	NULL
site	NULL
(	NULL
5'-cgtctcatgegatgcaaatcacttgagate-3	NULL
'	NULL
)	NULL
,	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
binding	NULL
site	NULL
(	NULL
5'-gatcgaggggactitccctage-3	NULL
'	NULL
)	NULL
,	NULL
and	NULL
,	NULL
finally	NULL
,	NULL
an	NULL
NF-AT-1	NULL
binding	NULL
sequence	NULL
(	NULL
5'-pgaggaaaaactetttcatacagaaggegt-3	NULL
'	NULL
)	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Competition	NULL
experiments	NULL
with	NULL
10	NULL
to	NULL
1,000	NULL
%	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotides	NULL
were	NULL
carried	NULL
out	NULL
to	NULL
identify	NULL
the	NULL
specific	NULL
complexes	NULL
.	NULL

For	NULL
supershift	NULL
analyses	NULL
,	NULL
polyclonal	NULL
antibodies	NULL
(	NULL
1	NULL
pg/reaction	NULL
)	NULL
directed	NULL
against	NULL
the	NULL
c-Fos	NULL
family	NULL
(	NULL
K-25	NULL
)	NULL
,	NULL
c-Fos	NULL
(	NULL
4-G	NULL
)	NULL
,	NULL
Fra-1	NULL
(	NULL
N-17	NULL
)	NULL
,	NULL
the	NULL
c-Jun	NULL
family	NULL
(	NULL
D	NULL
)	NULL
,	NULL
c-Jun/AP-1	NULL
(	NULL
N	NULL
)	NULL
,	NULL
JunB	NULL
(	NULL
210	NULL
)	NULL
,	NULL
and	NULL
JunD	NULL
(	NULL
329	NULL
)	NULL
were	NULL
used	NULL
.	NULL

All	NULL
antibodies	NULL
were	NULL
purchased	NULL
as	NULL
gel	NULL
supershift	NULL
reagents	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Rabbit	NULL
immunoglobulin	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
(	NULL
Dakopatts	NULL
,	NULL
Gentofte	NULL
,	NULL
Denmark	NULL
}	NULL
.	NULL

Statistics	NULL
.	NULL

Student	NULL
's	NULL
£	NULL
test	NULL
for	NULL
paired	NULL
data	NULL
was	NULL
used	NULL
for	NULL
statistical	NULL
calculations	NULL
.	NULL

Statistical	NULL
significance	NULL
was	NULL
set	NULL
at	NULL
P	NULL
=	NULL
0.05	NULL
.	NULL

RESULTS	NULL
Superinduced	NULL
early	NULL
gene	NULL
transcription	NULL
by	NULL
ciprofloxacin	NULL
in	NULL
primary	NULL
lymphocytes	NULL
.	NULL

We	NULL
have	NULL
earlier	NULL
demonstrated	NULL
that	NULL
ciprofloxacin	NULL
enhances	NULL
several	NULL
cytokine	NULL
mRNAs	NULL
,	NULL
including	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
in	NULL
PHA-activated	NULL
PBLs	NULL
incubated	NULL
for	NULL
24	NULL
to	NULL
72	NULL
h	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
characterize	NULL
the	NULL
early	NULL
kinetics	NULL
of	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
transcripts	NULL
,	NULL
total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
PHA-activated	NULL
PBLs	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
for	NULL
up	NULL
to	NULL
10	NULL
h.	NULL
Specific	NULL
cytokine	NULL
mRNAs	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
housekeeping	NULL
B-actin	NULL
message	NULL
were	NULL
analyzed	NULL
with	NULL
Northern	NULL
blots	NULL
with	NULL
radioactive	NULL
cDNA	NULL
probes	NULL
.	NULL

At	NULL
4	NULL
to	NULL
10	NULL
h	NULL
of	NULL
culture	NULL
,	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
mRNA	NULL
levels	NULL
were	NULL
significantly	NULL
increased	NULL
in	NULL
PBLs	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
compared	NULL
to	NULL
in	NULL
untreated	NULL
controls	NULL
.	NULL

Up	NULL
to	NULL
2.2-fold-more	NULL
IL-2	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
ciprofloxacin-treated	NULL
cells	NULL
as	NULL
early	NULL
as	NULL
6	NULL
h	NULL
after	NULL
PHA	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
increase	NULL
was	NULL
observed	NULL
when	NULL
IFN-y	NULL
mRNA	NULL
was	NULL
examined	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
ciprofloxacin-dependent	NULL
superinduction	NULL
of	NULL
cytokine	NULL
mRNAs	NULL
resulted	NULL
in	NULL
enhanced	NULL
cytokine	NULL
secretion	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

In	NULL
PBL	NULL
cultures	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
,	NULL
the	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
production	NULL
increased	NULL
10-	NULL
and	NULL
4-fold	NULL
,	NULL
respectively	NULL
.	NULL

Collective	NULL
data	NULL
from	NULL
our	NULL
previous	NULL
investigations	NULL
demon	NULL
Vou	NULL
.	NULL

42	NULL
,	NULL
1998	NULL
CIPROFLOXACIN	NULL
AND	NULL
MAMMALIAN	NULL
STRESS	NULL
RESPONSE	NULL
1925	NULL
A	NULL
B	NULL
C	NULL
180	NULL
160	NULL
60	NULL
r	NULL
1.2	NULL
160	NULL
80	NULL
lao	NULL
a	NULL
140	NULL
50	NULL
1.0	NULL
E	NULL
3:3	NULL
E	NULL
E	NULL
120	NULL
g	NULL
g	NULL
as	NULL
12	NULL
<	NULL
5	NULL
100	NULL
$	NULL
e	NULL
40	NULL
Los	NULL
_	NULL
Z	NULL
£2	NULL
100	NULL
€	NULL
>	NULL
<	NULL
5	NULL
Be	NULL
ES	NULL
E	NULL
§	NULL
so	NULL
3pm	NULL
30	NULL
Los	NULL
§4	NULL
o§	NULL
8	NULL
o	NULL
5	NULL
a	NULL
's	NULL
5C	NULL
>	NULL
€	NULL
>	NULL
£	NULL
60	NULL
o	NULL
3	NULL
g	NULL
{	NULL
6	NULL
60	NULL
<	NULL
S	NULL
U	NULL
20	NULL
-	NULL
0.4	NULL
a	NULL
€	NULL
40	NULL
&	NULL
*	NULL
``	NULL
~	NULL
7	NULL
20	NULL
2o	NULL
10	NULL
0.2	NULL
0	NULL
0	NULL
0	NULL
-	NULL
0	NULL
0	NULL
1	NULL
2	NULL
83	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Ciprofloxacin	NULL
:	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Kinetics	NULL
of	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
gene	NULL
expression	NULL
in	NULL
PBLs	NULL
exposed	NULL
to	NULL
ciprofloxacin	NULL
.	NULL

IL-2	NULL
(	NULL
A	NULL
)	NULL
and	NULL
IFN-y	NULL
(	NULL
B	NULL
)	NULL
mRNA	NULL
concentrations	NULL
were	NULL
analyzed	NULL
at	NULL
30	NULL
min	NULL
to	NULL
10	NULL
h	NULL
for	NULL
human	NULL
PHA-activated	NULL
PBLs	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
(	NULL
80	NULL
pg/ml	NULL
)	NULL
(	NULL
@	NULL
)	NULL
and	NULL
compared	NULL
to	NULL
those	NULL
in	NULL
drug-free	NULL
controls	NULL
(	NULL
0	NULL
)	NULL
.	NULL

At	NULL
24	NULL
h	NULL
,	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
concentrations	NULL
(	NULL
C	NULL
)	NULL
in	NULL
culture	NULL
supernatants	NULL
were	NULL
analyzed	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
,	NULL
and	NULL
Northern	NULL
blotting	NULL
was	NULL
performed	NULL
with	NULL
comparable	NULL
samples	NULL
of	NULL
RNA	NULL
.	NULL

Radioactive	NULL
cDNA	NULL
probes	NULL
specific	NULL
for	NULL
the	NULL
indicated	NULL
genes	NULL
were	NULL
sequentially	NULL
hybridized	NULL
to	NULL
the	NULL
filters	NULL
.	NULL

Scanning	NULL
densitometry	NULL
data	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
specific	NULL
cytokine	NULL
values	NULL
were	NULL
divided	NULL
by	NULL
the	NULL
corresponding	NULL
values	NULL
for	NULL
B-actin	NULL
mRNA	NULL
.	NULL

An	NULL
arbitrary	NULL
unit	NULL
was	NULL
defined	NULL
as	NULL
equal	NULL
amounts	NULL
of	NULL
cytokine	NULL
mRNA	NULL
and	NULL
B-actin	NULL
mRNA	NULL
.	NULL

No	NULL
cytokine	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
unstimulated	NULL
PBL	NULL
s	NULL
at	NULL
time	NULL
zero	NULL
and	NULL
was	NULL
set	NULL
as	NULL
0	NULL
arbitrary	NULL
units	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
in	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
and	NULL
blood	NULL
donors	NULL
.	NULL

(	NULL
C	NULL
)	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
were	NULL
analyzed	NULL
with	NULL
an	NULL
IL-2-dependent	NULL
cytotoxic	NULL
T-cell	NULL
line	NULL
and	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
,	NULL
respectively	NULL
.	NULL

Results	NULL
from	NULL
four	NULL
separate	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

Error	NULL
bars	NULL
in	NULL
panel	NULL
C	NULL
indicate	NULL
the	NULL
standard	NULL
deviation	NULL
.	NULL

P	NULL
<	NULL
0.01	NULL
and	NULL
P	NULL
<	NULL
0.001	NULL
for	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
,	NULL
respectively	NULL
.	NULL

strated	NULL
that	NULL
ciprofloxacin	NULL
enhances	NULL
IL-2	NULL
transcriptional	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
27	NULL
,	NULL
30	NULL
)	NULL
.	NULL

However	NULL
,	NULL
those	NULL
studies	NULL
were	NULL
performed	NULL
with	NULL
immortalized	NULL
cell	NULL
lines	NULL
that	NULL
in	NULL
many	NULL
ways	NULL
differ	NULL
from	NULL
primary	NULL
cells	NULL
.	NULL

To	NULL
characterize	NULL
gene	NULL
transcription	NULL
in	NULL
ciprofloxacin-treated	NULL
primary	NULL
lymphocytes	NULL
,	NULL
human	NULL
PBLs	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
a	NULL
construct	NULL
containing	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
enhancer	NULL
in	NULL
conjunction	NULL
with	NULL
a	NULL
simian	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
enhancer	NULL
element	NULL
linked	NULL
to	NULL
the	NULL
bacterial	NULL
reporter	NULL
gene	NULL
coding	NULL
for	NULL
CAT	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
CAT	NULL
plasmid	NULL
consisting	NULL
of	NULL
the	NULL
metallothionein	NULL
enhancer	NULL
and	NULL
promoter	NULL
(	NULL
instead	NULL
of	NULL
the	NULL
corresponding	NULL
part	NULL
of	NULL
IL-2	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

IL-2	NULL
promoter	NULL
activity	NULL
was	NULL
enhanced	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
an	NULL
increased	NULL
CAT	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
PBLs	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ciprofloxacin	NULL
at	NULL
80	NULL
pg/ml	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
when	NULL
metallothionein	NULL
enhancer	NULL
activity	NULL
was	NULL
examined	NULL
in	NULL
ciprofloxacin-treated	NULL
PBLs	NULL
,	NULL
CAT	NULL
activity	NULL
was	NULL
found	NULL
to	NULL
be	NULL
upregulated	NULL
.	NULL

Metallothionein	NULL
expression	NULL
in	NULL
PHA-activated	NULL
PBLs	NULL
increased	NULL
2.2-	NULL
and	NULL
4.3-fold	NULL
at	NULL
ciprofloxacin	NULL
concentrations	NULL
of	NULL
40	NULL
and	NULL
80	NULL
mg/ml	NULL
,	NULL
respectively	NULL
,	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
controls	NULL
without	NULL
ciprofloxacin	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
superinduced	NULL
metallothionein	NULL
gene	NULL
activity	NULL
was	NULL
considerably	NULL
stronger	NULL
than	NULL
the	NULL
IL-2	NULL
gene	NULL
induction	NULL
.	NULL

For	NULL
comparison	NULL
,	NULL
ciprofloxacin	NULL
at	NULL
40	NULL
and	NULL
80	NULL
pg/ml	NULL
increased	NULL
IL-2	NULL
gene	NULL
induction	NULL
1.3-	NULL
and	NULL
2.1-fold	NULL
,	NULL
respectively	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
augmented	NULL
gene	NULL
transcription	NULL
by	NULL
ciprofloxacin	NULL
was	NULL
not	NULL
specific	NULL
for	NULL
lymphocyte-derived	NULL
cytokines	NULL
.	NULL

Effect	NULL
of	NULL
ciprofloxacin	NULL
on	NULL
transcription	NULL
factor	NULL
activity	NULL
in	NULL
primary	NULL
lymphocytes	NULL
.	NULL

Since	NULL
ciprofloxacin	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
interfere	NULL
with	NULL
transcription	NULL
factors	NULL
in	NULL
the	NULL
two	NULL
T-cell	NULL
lymphoma	NULL
cell	NULL
lines	NULL
Jurkat	NULL
and	NULL
EL-4	NULL
(	NULL
27	NULL
,	NULL
30	NULL
)	NULL
,	NULL
the	NULL
next	NULL
step	NULL
was	NULL
to	NULL
examine	NULL
the	NULL
transcription	NULL
factors	NULL
AP-1	NULL
,	NULL
NF-AT-1	NULL
,	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
T	NULL
cells	NULL
purified	NULL
from	NULL
peripheral	NULL
blood	NULL
.	NULL

To	NULL
exclude	NULL
monocytes	NULL
and	NULL
B	NULL
lymphocytes	NULL
,	NULL
CD3	NULL
*	NULL
CD4	NULL
*	NULL
lymphocytes	NULL
(	NULL
T	NULL
helper	NULL
cells	NULL
)	NULL
were	NULL
isolated	NULL
by	NULL
negative	NULL
selection	NULL
with	NULL
magnetic	NULL
beads	NULL
.	NULL

Total	NULL
cell	NULL
protein	NULL
was	NULL
isolated	NULL
from	NULL
PHA-	NULL
and	NULL
PMA-activated	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
at	NULL
1	NULL
to	NULL
4	NULL
h	NULL
and	NULL
incubated	NULL
with	NULL
a	NULL
°°P-labelled	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
an	NULL
AP-1	NULL
consensus	NULL
binding	NULL
site	NULL
.	NULL

When	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
analyzed	NULL
by	NULL
PAGE	NULL
,	NULL
a	NULL
distinct	NULL
pattern	NULL
appeared	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

At	NULL
>	NULL
3	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
a	NULL
higher	NULL
level	NULL
of	NULL
AP-1	NULL
binding	NULL
was	NULL
detected	NULL
in	NULL
CD4*	NULL
T-cell	NULL
extracts	NULL
purified	NULL
from	NULL
activated	NULL
cells	NULL
incubated	NULL
with	NULL
ciprofioxa-	NULL
cin	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
drug-free	NULL
controls	NULL
.	NULL

To	NULL
verify	NULL
that	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixtures	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
also	NULL
analyzed	NULL
for	NULL
Oct-1	NULL
binding	NULL
that	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
invariable	NULL
during	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mean	NULL
AP-1	NULL
binding	NULL
activities	NULL
divided	NULL
by	NULL
corresponding	NULL
values	NULL
for	NULL
Oct-1	NULL
are	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
the	NULL
same	NULL
cell	NULL
extracts	NULL
were	NULL
examined	NULL
for	NULL
NF-AT-1	NULL
or	NULL
NF-kB	NULL
binding	NULL
,	NULL
we	NULL
did	NULL
not	NULL
observe	NULL
any	NULL
difference	NULL
between	NULL
ciprofloxacin-treated	NULL
cells	NULL
and	NULL
controls	NULL
incubated	NULL
without	NULL
any	NULL
drug	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
further	NULL
characterize	NULL
the	NULL
different	NULL
proteins	NULL
included	NULL
in	NULL
the	NULL
AP-1	NULL
complex	NULL
detected	NULL
in	NULL
T	NULL
cells	NULL
exposed	NULL
to	NULL
ciprofloxacin	NULL
,	NULL
supershifts	NULL
were	NULL
performed	NULL
.	NULL

The	NULL
reaction	NULL
mixtures	NULL
were	NULL
supplemented	NULL
with	NULL
polyclonal	NULL
antibodies	NULL
directed	NULL
against	NULL
the	NULL
specific	NULL
members	NULL
of	NULL
the	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
families	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
radioactive	NULL
AP-1	NULL
oligonucleotide	NULL
.	NULL

Cytoplasmic	NULL
protein	NULL
isolated	NULL
from	NULL
the	NULL
3-h	NULL
time	NULL
point	NULL
with	NULL
ciprofloxacin	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
was	NULL
analyzed	NULL
for	NULL
AP-1	NULL
components	NULL
.	NULL

The	NULL
upper	NULL
band	NULL
showed	NULL
the	NULL
specific	NULL
AP-1	NULL
binding	NULL
,	NULL
as	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
1	NULL
.	NULL

The	NULL
AP-1	NULL
shift	NULL
disappeared	NULL
when	NULL
the	NULL
polyclonal	NULL
antiserum	NULL
against	NULL
the	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
family	NULL
of	NULL
proteins	NULL
was	NULL
added	NULL
,	NULL
as	NULL
illustrated	NULL
in	NULL
lane	NULL
2	NULL
(	NULL
pan-c-Fos	NULL
)	NULL
and	NULL
lane	NULL
6	NULL
(	NULL
pan-c-Jun	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Rabbit	NULL
immunoglobulin	NULL
,	NULL
a	NULL
negative	NULL
antibody	NULL
control	NULL
,	NULL
did	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
specific	NULL
AP-1	NULL
band	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
AP-1	NULL
complex	NULL
mainly	NULL
consisted	NULL
of	NULL
the	NULL
FosB	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
JunD	NULL
proteins	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
,	NULL
however	NULL
,	NULL
was	NULL
seen	NULL
in	NULL
ciprofloxacin-free	NULL
control	NULL
extracts	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
upregulated	NULL
AP-1	NULL
activity	NULL
observed	NULL
in	NULL
ciprofloxacin-treated	NULL
T	NULL
cells	NULL
was	NULL
indeed	NULL
specific	NULL
because	NULL
it	NULL
consisted	NULL
of	NULL
proteins	NULL
from	NULL
the	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
families	NULL
.	NULL

Increased	NULL
concentrations	NULL
of	NULL
immediate-early	NULL
expressed	NULL
mRNAs	NULL
in	NULL
ciprofloxacin-treated	NULL
PBLs	NULL
.	NULL

Metallothioneins	NULL
that	NULL
protect	NULL
cells	NULL
against	NULL
oxidative	NULL
stress	NULL
are	NULL
induced	NULL
by	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
different	NULL
stimuli	NULL
,	NULL
including	NULL
metals	NULL
and	NULL
UV	NULL
C	NULL
radiation	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
observed	NULL
hyperinduced	NULL
metallothionein	NULL
transcription	NULL
in	NULL
addition	NULL
to	NULL
increased	NULL
AP-1	NULL
activity	NULL
suggested	NULL
that	NULL
a	NULL
phenomenon	NULL
similar	NULL
to	NULL
a	NULL
stress	NULL
response	NULL
occurred	NULL
in	NULL
PBLs	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
.	NULL

This	NULL
urged	NULL
us	NULL
to	NULL
examine	NULL
the	NULL
expression	NULL
of	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
and	NULL
c-myc	NULL
mRNAs	NULL
,	NULL
which	NULL
is	NULL
commonly	NULL
related	NULL
to	NULL
mammalian	NULL
stress	NULL
responses	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
effect	NULL
of	NULL
ciprofloxacin	NULL
on	NULL
these	NULL
immediate-early	NULL
gene	NULL
tran	NULL
1926	NULL
RIESBECK	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
SV-IL-2-CAT	NULL
MT-CAT-SV	NULL
Ciprofloxacin	NULL
:	NULL
!	NULL

._	NULL
J	NULL
I	NULL
T	NULL
iM	NULL
J	NULL
U	NULL
J	NULL
Mitogen	NULL
:	NULL
-	NULL
m	NULL
+	NULL
+	NULL
M	NULL
n	NULL
+	NULL
+	NULL
fd	NULL
i	NULL
_	NULL
Relative	NULL
CAT	NULL
-activity	NULL
(	NULL
%	NULL
of	NULL
untreated	NULL
cells	NULL
)	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Ciprofloxacin-dependent	NULL
increase	NULL
of	NULL
IL-2	NULL
and	NULL
metallothioncin	NULL
enhancer	NULL
and	NULL
promoter	NULL
regions	NULL
in	NULL
stimulated	NULL
PBLs	NULL
.	NULL

Raw	NULL
data	NULL
are	NULL
shown	NULL
for	NULL
IL-2	NULL
and	NULL
metallothionein	NULL
,	NULL
indicated	NULL
by	NULL
SV-IL-2-CAT	NULL
and	NULL
MT-CAT-SV	NULL
,	NULL
respectively	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Relative	NULL
CAT	NULL
activities	NULL
for	NULL
ciprofloxacin-treated	NULL
PBL	NULL
are	NULL
also	NULL
presented	NULL
(	NULL
B	NULL
)	NULL
.	NULL

PBLs	NULL
were	NULL
stimulated	NULL
(	NULL
1	NULL
ag	NULL
of	NULL
PHA	NULL
per	NULL
ml	NULL
and	NULL
50	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
)	NULL
for	NULL
18	NULL
h	NULL
,	NULL
at	NULL
which	NULL
time	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
indicated	NULL
plasmids	NULL
and	NULL
rested	NULL
.	NULL

After	NULL
36	NULL
h	NULL
,	NULL
PBLs	NULL
were	NULL
rechallenged	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
PHA	NULL
per	NULL
ml	NULL
and	NULL
incubated	NULL
with	NULL
or	NULL
without	NULL
ciprofloxacin	NULL
(	NULL
40	NULL
or	NULL
80	NULL
pg/ml	NULL
)	NULL
.	NULL

After	NULL
an	NULL
additional	NULL
15	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
analyzed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

For	NULL
quantification	NULL
,	NULL
areas	NULL
containing	NULL
the	NULL
acetylated	NULL
and	NULL
nonacetylated	NULL
forms	NULL
of	NULL
chloramphenicol	NULL
were	NULL
cut	NULL
out	NULL
from	NULL
thin-layer	NULL
chromatography	NULL
plates	NULL
and	NULL
measured	NULL
with	NULL
a	NULL
scintillation	NULL
counter	NULL
.	NULL

Six	NULL
independent	NULL
donors	NULL
were	NULL
examined	NULL
on	NULL
six	NULL
different	NULL
occasions	NULL
.	NULL

Duplicates	NULL
were	NULL
included	NULL
in	NULL
all	NULL
experiments	NULL
.	NULL

Error	NULL
bars	NULL
indicate	NULL
the	NULL
standard	NULL
error	NULL
of	NULL
the	NULL
mean	NULL
.	NULL

Values	NULL
for	NULL
ciprofloxacin-treated	NULL
PBLs	NULL
were	NULL
significantly	NULL
different	NULL
from	NULL
those	NULL
of	NULL
the	NULL
controls	NULL
.	NULL

SV-IL-2-CAT	NULL
,	NULL
P	NULL
<	NULL
0.05	NULL
and	NULL
P	NULL
<	NULL
0.01	NULL
for	NULL
ciprofloxacin	NULL
at	NULL
40	NULL
and	NULL
80	NULL
pg/ml	NULL
,	NULL
respectively	NULL
.	NULL

MT-CAT-SV	NULL
,	NULL
P	NULL
<	NULL
0.001	NULL
and	NULL
P	NULL
<	NULL
0.05	NULL
for	NULL
ciprofloxacin	NULL
at	NULL
40	NULL
and	NULL
80	NULL
ug/ml	NULL
,	NULL
respectively	NULL
.	NULL

scripts	NULL
,	NULL
PBLs	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
and	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
(	NULL
80	NULL
pg/ml	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
analysis	NULL
of	NULL
steady-state	NULL
mRNA	NULL
levels	NULL
at	NULL
various	NULL
time	NULL
points	NULL
.	NULL

No	NULL
major	NULL
differences	NULL
were	NULL
observed	NULL
between	NULL
ciprofloxacin-treated	NULL
and	NULL
control	NULL
PBL	NULL
s	NULL
during	NULL
the	NULL
first	NULL
20	NULL
min	NULL
of	NULL
culture	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
after	NULL
30	NULL
to	NULL
120	NULL
min	NULL
of	NULL
incubation	NULL
,	NULL
more	NULL
c-fos	NULL
and	NULL
c-jun	NULL
mRNAs	NULL
were	NULL
detected	NULL
in	NULL
cells	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
than	NULL
in	NULL
drug-free	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
increased	NULL
mRNA	NULL
levels	NULL
found	NULL
in	NULL
cells	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
were	NULL
present	NULL
up	NULL
to	NULL
10	NULL
h	NULL
of	NULL
incubation	NULL
.	NULL

After	NULL
4	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
ciprofloxacin	NULL
did	NULL
not	NULL
,	NULL
however	NULL
,	NULL
enhance	NULL
steady-state	NULL
mRNA	NULL
concentrations	NULL
above	NULL
the	NULL
initial	NULL
mRNA	NULL
levels	NULL
detected	NULL
at	NULL
30	NULL
to	NULL
60	NULL
min	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
c-fos	NULL
and	NULL
c-jun	NULL
mRNAs	NULL
,	NULL
c-mye	NULL
mRNA	NULL
was	NULL
expressed	NULL
earlier	NULL
in	NULL
ciprofioxacin-treated	NULL
PBLs	NULL
(	NULL
at	NULL
2	NULL
to	NULL
6	NULL
h	NULL
)	NULL
than	NULL
in	NULL
the	NULL
drug-free	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
kinetics	NULL
of	NULL
these	NULL
immediate-early	NULL
induced	NULL
genes	NULL
were	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
kinetics	NULL
for	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
mRNAs	NULL
,	NULL
whose	NULL
expression	NULL
is	NULL
dependent	NULL
ANTIMICROB	NULL
.	NULL

AGENTS	NULL
CHEMOTHER	NULL
.	NULL

on	NULL
,	NULL
among	NULL
other	NULL
proteins	NULL
,	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
.	NULL

The	NULL
steady-state	NULL
cytokine	NULL
mRNA	NULL
levels	NULL
increased	NULL
at	NULL
>	NULL
4	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
and	NULL
B	NULL
)	NULL
,	NULL
a	NULL
time	NULL
point	NULL
when	NULL
the	NULL
immediate-early	NULL
mRNAs	NULL
already	NULL
had	NULL
started	NULL
accumulating	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
ciprofioxacin-treated	NULL
cells	NULL
,	NULL
the	NULL
activated	NULL
AP-1	NULL
found	NULL
at	NULL
>	NULL
2	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
paralleled	NULL
the	NULL
increased	NULL
c-jun	NULL
and	NULL
c-fos	NULL
mRNA	NULL
steady-state	NULL
levels	NULL
detected	NULL
at	NULL
>	NULL
30	NULL
min	NULL
.	NULL

Ciprofloxacin	NULL
did	NULL
not	NULL
stabilize	NULL
the	NULL
immediate-early	NULL
expressed	NULL
gene	NULL
transcripts	NULL
.	NULL

To	NULL
exclude	NULL
whether	NULL
ciprofloxacin	NULL
influenced	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
and	NULL
c-mye	NULL
mRNA	NULL
degradation	NULL
,	NULL
ciprofloxacin	NULL
with	NULL
or	NULL
without	NULL
the	NULL
transcriptional	NULL
inhibitor	NULL
actinomycin	NULL
D	NULL
was	NULL
added	NULL
to	NULL
PBLs	NULL
that	NULL
had	NULL
been	NULL
stimulated	NULL
with	NULL
PHA	NULL
for	NULL
6	NULL
h.	NULL
Different	NULL
mRNAs	NULL
were	NULL
analyzed	NULL
after	NULL
2	NULL
and	NULL
4	NULL
h	NULL
of	NULL
the	NULL
actinomycin	NULL
D	NULL
and/or	NULL
ciprofloxacin	NULL
chase	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
7	NULL
to	NULL
12	NULL
)	NULL
.	NULL

Irrespective	NULL
of	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
ciprofloxacin	NULL
,	NULL
c-myc	NULL
,	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
junB	NULL
,	NULL
fra-1	NULL
,	NULL
and	NULL
IL-2	NULL
mRNAs	NULL
were	NULL
all	NULL
degraded	NULL
in	NULL
actinomycin	NULL
D-treated	NULL
cells	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
when	NULL
new	NULL
mRNA	NULL
transcription	NULL
was	NULL
inhibited	NULL
by	NULL
actinomycin	NULL
D	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
ciprofloxacin	NULL
did	NULL
not	NULL
influence	NULL
the	NULL
half-life	NULL
of	NULL
the	NULL
immediate-early	NULL
transcripts	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
actinomycin	NULL
D	NULL
,	NULL
the	NULL
various	NULL
mR	NULL
A	NULL
Control	NULL
Ciprofloxacin	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
:	NULL
0	NULL
I1	NULL
2	NULL
)	NULL
3	NULL
4|n.p.|1	NULL
2	NULL
)	NULL
3	NULL
)	NULL
4	NULL
#	NULL
@	NULL
..	NULL
+	NULL
©	NULL
AP-1	NULL
-p	NULL
.	NULL

h	NULL
free	NULL
probe	NULL
-	NULL
>	NULL
B	NULL
40	NULL
2	NULL
ho	NULL
30	NULL
``	NULL
``	NULL
2	NULL
g	NULL
a	NULL
€	NULL
<	NULL
Z	NULL
3	NULL
g	NULL
20	NULL
S	NULL
€	NULL
i	NULL
S	NULL
G	NULL
10	NULL
CC	NULL
0	NULL
T	NULL
T	NULL
L	NULL
I	NULL
T	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Increased	NULL
AP-1	NULL
binding	NULL
activity	NULL
in	NULL
stimulated	NULL
CD4*	NULL
T	NULL
cells	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
.	NULL

A	NULL
typical	NULL
AP-1	NULL
shift	NULL
is	NULL
shown	NULL
for	NULL
activated	NULL
purified	NULL
T	NULL
helper	NULL
cells	NULL
incubated	NULL
with	NULL
(	NULL
@	NULL
)	NULL
or	NULL
without	NULL
(	NULL
BBD	NULL
)	NULL
)	NULL
ciprofloxacin	NULL
(	NULL
80	NULL
pg/ml	NULL
)	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Scanning	NULL
densitometry	NULL
data	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
also	NULL
shown	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Total	NULL
cell	NULL
protein	NULL
was	NULL
isolated	NULL
from	NULL
a	NULL
pure	NULL
population	NULL
of	NULL
T	NULL
helper	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
activated	NULL
with	NULL
PHA	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

Protein	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
radioactive	NULL
oligonucleotides	NULL
and	NULL
analyzed	NULL
by	NULL
PAGE	NULL
.	NULL

n.p	NULL
.	NULL

,	NULL
a	NULL
reaction	NULL
without	NULL
any	NULL
protein	NULL
.	NULL

In	NULL
panel	NULL
B	NULL
,	NULL
1	NULL
arbitrary	NULL
unit	NULL
was	NULL
defined	NULL
as	NULL
equal	NULL
amounts	NULL
of	NULL
AP-1	NULL
and	NULL
Oct-1	NULL
.	NULL

No	NULL
AP-1	NULL
binding	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
unstimulated	NULL
cells	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
.	NULL

VoL	NULL
.	NULL

42	NULL
,	NULL
1998	NULL
A	NULL
o	NULL
&	NULL
foj	NULL
§g§°qw	NULL
s	NULL
?	NULL

we	NULL
”	NULL
?	NULL

6	NULL
8C	NULL
&	NULL
C	NULL
o	NULL
a	NULL
£	NULL
4	NULL
s	NULL
5	NULL
$	NULL
a	NULL
§	NULL
&	NULL
2	NULL
PF	NULL
§	NULL
$	NULL
&	NULL
Lane	NULL
12134	NULL
5	NULL
6	NULL
,	NULL
7	NULL
,	NULL
£	NULL
,	NULL
9	NULL
19	NULL
<	NULL
»	NULL
AP-1	NULL
-p	NULL
»	NULL
t	NULL
.	NULL

wn	NULL
.	NULL

‘	NULL
Q	NULL
w	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

The	NULL
superinduced	NULL
AP-1	NULL
complex	NULL
in	NULL
ciprofloxacin-treated	NULL
CD4*	NULL
T	NULL
cells	NULL
contained	NULL
proteins	NULL
from	NULL
the	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
families	NULL
.	NULL

Cell	NULL
extract	NULL
from	NULL
the	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
exposed	NULL
to	NULL
ciprofloxacin	NULL
for	NULL
3	NULL
h	NULL
displayed	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
was	NULL
examined	NULL
in	NULL
supershifts	NULL
.	NULL

The	NULL
upper	NULL
band	NULL
shows	NULL
the	NULL
specific	NULL
AP-1	NULL
binding	NULL
(	NULL
see	NULL
,	NULL
for	NULL
example	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
band	NULL
shows	NULL
the	NULL
unspecific	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
oligonucleotide	NULL
sometimes	NULL
observed	NULL
.	NULL

Rabbit	NULL
polyclonal	NULL
antibodies	NULL
were	NULL
prein-cubated	NULL
with	NULL
the	NULL
extracts	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
AP-1	NULL
oligonucleotide	NULL
.	NULL

Unspecific	NULL
rabbit	NULL
immunoglobulins	NULL
,	NULL
which	NULL
were	NULL
used	NULL
as	NULL
a	NULL
control	NULL
serum	NULL
,	NULL
are	NULL
indicated	NULL
by	NULL
rabbit	NULL
immunoglobulin	NULL
G	NULL
(	NULL
IgG	NULL
)	NULL
in	NULL
lane	NULL
10	NULL
.	NULL

The	NULL
free	NULL
probe	NULL
(	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
was	NULL
run	NULL
out	NULL
from	NULL
the	NULL
gel	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
the	NULL
2-h	NULL
extract	NULL
from	NULL
control	NULL
T	NULL
cells	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
(	NULL
data	NULL
not	NULL
presented	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
representative	NULL
for	NULL
two	NULL
different	NULL
blood	NULL
donors	NULL
.	NULL

NAs	NULL
were	NULL
found	NULL
to	NULL
be	NULL
upregulated	NULL
by	NULL
ciprofloxacin	NULL
after	NULL
both	NULL
2	NULL
and	NULL
4	NULL
additional	NULL
h	NULL
of	NULL
culture	NULL
,	NULL
indicating	NULL
that	NULL
even	NULL
a	NULL
short	NULL
exposure	NULL
to	NULL
the	NULL
drug	NULL
resulted	NULL
in	NULL
increased	NULL
mRNA	NULL
concentrations	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
6	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
2.6-	NULL
and	NULL
2.7-fold	NULL
increases	NULL
of	NULL
c-jun	NULL
and	NULL
junB	NULL
mRNA	NULL
levels	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
detected	NULL
after	NULL
a	NULL
4-h	NULL
ciprofloxacin	NULL
pulse	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
control	NULL
mRNA	NULL
,	NULL
B-actin	NULL
,	NULL
was	NULL
unaffected	NULL
by	NULL
ciprofloxacin	NULL
.	NULL

DISCUSSION	NULL
In	NULL
the	NULL
present	NULL
investigation	NULL
,	NULL
we	NULL
show	NULL
that	NULL
the	NULL
quinolone	NULL
antibiotic	NULL
ciprofloxacin	NULL
induces	NULL
a	NULL
mammalian	NULL
stress	NULL
response	NULL
similar	NULL
to	NULL
the	NULL
SOS	NULL
response	NULL
seen	NULL
in	NULL
bacteria	NULL
.	NULL

The	NULL
extent	NULL
to	NULL
which	NULL
the	NULL
implications	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
fluoroquinolones	NULL
on	NULL
PBLs	NULL
observed	NULL
in	NULL
the	NULL
present	NULL
study	NULL
are	NULL
of	NULL
clinical	NULL
interest	NULL
is	NULL
difficult	NULL
to	NULL
establish	NULL
,	NULL
since	NULL
the	NULL
effects	NULL
were	NULL
observed	NULL
at	NULL
intermediate	NULL
and	NULL
high	NULL
quinolone	NULL
concentrations	NULL
not	NULL
reached	NULL
in	NULL
CIPROFLOXACIN	NULL
AND	NULL
MAMMALIAN	NULL
STRESS	NULL
RESPONSE	NULL
1927	NULL
patients	NULL
.	NULL

However	NULL
,	NULL
the	NULL
most	NULL
likely	NULL
parallels	NULL
can	NULL
be	NULL
drawn	NULL
with	NULL
the	NULL
effects	NULL
of	NULL
clinically	NULL
achievable	NULL
concentrations	NULL
of	NULL
ciprofloxacin	NULL
.	NULL

It	NULL
is	NULL
well	NULL
established	NULL
that	NULL
ciprofloxacin	NULL
and	NULL
other	NULL
quinolones	NULL
at	NULL
5	NULL
ug/ml	NULL
increase	NULL
IL-2	NULL
production	NULL
in	NULL
both	NULL
human	NULL
and	NULL
murine	NULL
in	NULL
vitro	NULL
systems	NULL
,	NULL
but	NULL
also	NULL
that	NULL
a	NULL
maximal	NULL
effect	NULL
is	NULL
observed	NULL
at	NULL
80	NULL
ug/ml	NULL
(	NULL
26	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
relatively	NULL
insensitive	NULL
methods	NULL
presently	NULL
available	NULL
,	NULL
we	NULL
did	NULL
not	NULL
detect	NULL
any	NULL
IL-2	NULL
mRNA	NULL
increase	NULL
at	NULL
5	NULL
pg/ml	NULL
but	NULL
only	NULL
detected	NULL
increases	NULL
at	NULL
20	NULL
and	NULL
80	NULL
pg/ml	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
the	NULL
augmented	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
and	NULL
metallothionein	NULL
genes	NULL
was	NULL
observed	NULL
at	NULL
>	NULL
40	NULL
pg/ml	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Recently	NULL
published	NULL
reports	NULL
on	NULL
immunomodulatory	NULL
effects	NULL
of	NULL
ciprofloxacin	NULL
in	NULL
vivo	NULL
support	NULL
our	NULL
hypothesis	NULL
.	NULL

For	NULL
example	NULL
,	NULL
when	NULL
ciprofloxacin	NULL
at	NULL
clinically	NULL
relevant	NULL
doses	NULL
was	NULL
administered	NULL
to	NULL
sublethally	NULL
irradiated	NULL
mice	NULL
,	NULL
hematopoiesis	NULL
was	NULL
stimu-lated	NULL
,	NULL
most	NULL
probably	NULL
due	NULL
to	NULL
induction	NULL
of	NULL
granulocyte-macro-phage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
and	NULL
IL-3	NULL
(	NULL
19	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Despite	NULL
the	NULL
high	NULL
concentrations	NULL
of	NULL
ciprofloxacin	NULL
(	NULL
80	NULL
pg/ml	NULL
)	NULL
that	NULL
were	NULL
required	NULL
for	NULL
us	NULL
to	NULL
sense	NULL
a	NULL
significant	NULL
response	NULL
in	NULL
vitro	NULL
,	NULL
augmented	NULL
GM-CSF	NULL
and	NULL
IL-3	NULL
mRNA	NULL
levels	NULL
were	NULL
observed	NULL
in	NULL
mitogen-activated	NULL
PBLs	NULL
exposed	NULL
to	NULL
ciprofloxacin	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Another	NULL
example	NULL
of	NULL
a	NULL
relationship	NULL
between	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
findings	NULL
was	NULL
recently	NULL
published	NULL
by	NULL
Wrishko	NULL
et	NULL
al	NULL
.	NULL

(	NULL
41	NULL
)	NULL
.	NULL

In	NULL
their	NULL
study	NULL
,	NULL
a	NULL
pharmacodynamic	NULL
interaction	NULL
between	NULL
cyclosporine	NULL
A	NULL
and	NULL
ciprofloxacin	NULL
was	NULL
demonstrated	NULL
in	NULL
renal	NULL
transplant	NULL
patients	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
antibacterial	NULL
agent	NULL
may	NULL
be	NULL
immunomodulatory	NULL
,	NULL
particularly	NULL
when	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
(	NULL
41	NULL
)	NULL
.	NULL

The	NULL
corresponding	NULL
in	NULL
vitro	NULL
finding	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
a	NULL
cyclosporine	NULL
A-dependent	NULL
immunosuppressive	NULL
effect	NULL
on	NULL
cytokine	NULL
synthesis	NULL
counteracted	NULL
by	NULL
the	NULL
quinolone	NULL
,	NULL
was	NULL
observed	NULL
at	NULL
>	NULL
20	NULL
pg	NULL
of	NULL
ciprofloxacin	NULL
per	NULL
ml	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
collective	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
upregulated	NULL
IL-2	NULL
synthesis	NULL
observed	NULL
in	NULL
PBLs	NULL
incubated	NULL
with	NULL
low	NULL
concentrations	NULL
of	NULL
ciprofloxacin	NULL
may	NULL
reflect	NULL
a	NULL
stress	NULL
response	NULL
.	NULL

However	NULL
,	NULL
ciprofloxacin	NULL
at	NULL
high	NULL
concentrations	NULL
was	NULL
required	NULL
in	NULL
vitro	NULL
to	NULL
clearly	NULL
demonstrate	NULL
the	NULL
relation-ship	NULL
.	NULL

During	NULL
treatment	NULL
of	NULL
mammalian	NULL
cells	NULL
with	NULL
,	NULL
for	NULL
example	NULL
,	NULL
cytotoxic	NULL
drugs	NULL
or	NULL
heavy	NULL
metals	NULL
,	NULL
a	NULL
stress	NULL
response	NULL
is	NULL
generally	NULL
triggered	NULL
,	NULL
resulting	NULL
in	NULL
induction	NULL
of	NULL
several	NULL
different	NULL
genes	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

Increased	NULL
concentrations	NULL
of	NULL
transcriptional	NULL
regulation	NULL
factors	NULL
(	NULL
27	NULL
,	NULL
30	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
upregulated	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
and	NULL
cytokine	NULL
gene	NULL
transcripts	NULL
in	NULL
stimulated	NULL
eukaryotic	NULL
cells	NULL
exposed	NULL
to	NULL
ciprofloxacin	NULL
suggest	NULL
that	NULL
ciprofloxacin	NULL
might	NULL
have	NULL
induced	NULL
a	NULL
stress	NULL
response	NULL
similar	NULL
to	NULL
a	NULL
mammalian	NULL
DNA	NULL
damage	NULL
response	NULL
160	NULL
160	NULL
160	NULL
in	NULL
140	NULL
-	NULL
io	NULL
140	NULL
-	NULL
140	NULL
a	NULL
@	NULL
a	NULL
»	NULL
©	NULL
_	NULL
©	NULL
_	NULL
o	NULL
$	NULL
@	NULL
120	NULL
5g	NULL
120	NULL
§§1zo	NULL
g	NULL
§	NULL
100	NULL
-	NULL
35	NULL
199	NULL
-	NULL
<	NULL
5	NULL
199	NULL
CC	NULL
go	NULL
_	NULL
C	NULL
C	NULL
go	NULL
_	NULL
{	NULL
E	NULL
Togo	NULL
]	NULL
2	NULL
5	NULL
c	NULL
©	NULL
2	NULL
8	NULL
§§	NULL
67	NULL
$	NULL
8	NULL
so-	NULL
#	NULL
B	NULL
so	NULL
42	NULL
4	NULL
*	NULL
©	NULL
a	NULL
-	NULL
a	NULL
-	NULL
a-©	NULL
40	NULL
-	NULL
©	NULL
40	NULL
-	NULL
s	NULL
40	NULL
~	NULL
CC	NULL
CC	NULL
CC	NULL
20	NULL
-	NULL
20	NULL
-	NULL
20	NULL
0	NULL
T	NULL
T-r-1T-T-J	NULL
T	NULL
0	NULL
+	NULL
0	NULL
0	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
10	NULL
0	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
506	NULL
7	NULL
&	NULL
9	NULL
10	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Kinetics	NULL
of	NULL
immediate-early	NULL
gene	NULL
transcripts	NULL
in	NULL
stimulated	NULL
PBLs	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
.	NULL

Northern	NULL
blot	NULL
results	NULL
are	NULL
shown	NULL
for	NULL
c-fos	NULL
(	NULL
A	NULL
)	NULL
,	NULL
c-jun	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
c-myc	NULL
(	NULL
C	NULL
)	NULL
mRNA	NULL
expression	NULL
between	NULL
30	NULL
min	NULL
and	NULL
10	NULL
h	NULL
with	NULL
(	NULL
@	NULL
)	NULL
or	NULL
without	NULL
(	NULL
0	NULL
)	NULL
ciprofloxacin	NULL
.	NULL

PBL	NULL
s	NULL
were	NULL
isolated	NULL
from	NULL
healthy	NULL
donors	NULL
,	NULL
and	NULL
PHA	NULL
(	NULL
1	NULL
g/m	NULL
!	NULL
)	NULL

in	NULL
addition	NULL
to	NULL
ciprofloxacin	NULL
(	NULL
80	NULL
pg/ml	NULL
)	NULL
was	NULL
added	NULL
at	NULL
culture	NULL
initiation	NULL
.	NULL

Specific	NULL
mRNAs	NULL
were	NULL
analyzed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

One	NULL
typical	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
is	NULL
shown	NULL
.	NULL

1928	NULL
RIESBECK	NULL
ET	NULL
AL	NULL
.	NULL

Act	NULL
D	NULL
+	NULL
Control	NULL
Ciprofloxacin	NULL
Act	NULL
D	NULL
ciprofloxacin	NULL
1	NULL
C	NULL
1	NULL
Time	NULL
(	NULL
m	NULL
:	NULL
``	NULL
o	NULL
2	NULL
4	NULL
``	NULL
o	NULL
2	NULL
4°	NULL
o	NULL
204	NULL
o	NULL
20	NULL
4	NULL
cmy	NULL
:	NULL
>	NULL
|	NULL
@	NULL
@	NULL
®	NULL
.	NULL

“	NULL
p	NULL
@	NULL
100	NULL
89	NULL
72	NULL
126	NULL
136	NULL
1	NULL
1	NULL
3	NULL
1	NULL
c-fos	NULL
-|	NULL
«	NULL
®	NULL
%	NULL
‘	NULL
«	NULL
#	NULL
we	NULL
C	NULL
100	NULL
-	NULL
60	NULL
9	NULL
240	NULL
200	NULL
1	NULL
0	NULL
5	NULL
1	NULL
I	NULL
6	NULL
_	NULL
‘	NULL
-=	NULL
c-jun	NULL
-|	NULL
~*	NULL
M	NULL
l	NULL
``	NULL
E	NULL
100	NULL
-	NULL
160	NULL
149	NULL
251	NULL
266	NULL
2	NULL
1	NULL
1	NULL
1	NULL
JunB	NULL
#	NULL
|	NULL
wa	NULL
%	NULL
W	NULL
``	NULL
@	NULL
#	NULL
A	NULL
.	NULL

``	NULL
__	NULL
8	NULL
100	NULL
84	NULL
49	NULL
276	NULL
270	NULL
3	NULL
3	NULL
13	NULL
3	NULL
Fra-\	NULL
-	NULL
``	NULL
ir	NULL
i	NULL
``	NULL
‘	NULL
LI	NULL
``	NULL
t	NULL
|	NULL
100	NULL
88	NULL
75	NULL
125	NULL
-	NULL
140	NULL
20	NULL
0	NULL
0	NULL
0	NULL
L2	NULL
»	NULL
|	NULL
#	NULL
®	NULL
l	NULL
``	NULL
0	NULL
o	NULL
-	NULL
0s	NULL
100	NULL
-	NULL
83	NULL
49	NULL
138	NULL
165	NULL
46	NULL
36	NULL
42	NULL
.	NULL

38	NULL
``	NULL
F	NULL
oT	NULL
n	NULL
-|	NULL
@	NULL
@	NULL
@	NULL
@	NULL
@	NULL
@	NULL
@	NULL
#	NULL
0+	NULL
@	NULL
0	NULL
pe	NULL
.	NULL

Lane	NULL
:	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Ciprofloxacin	NULL
does	NULL
not	NULL
influence	NULL
the	NULL
half-lives	NULL
of	NULL
immediate-early	NULL
gene	NULL
transcripts	NULL
in	NULL
activated	NULL
PBLs	NULL
.	NULL

Northern	NULL
blot	NULL
results	NULL
are	NULL
shown	NULL
for	NULL
e-myc	NULL
,	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
junB	NULL
,	NULL
and	NULL
fra-1	NULL
mRNAs	NULL
.	NULL

For	NULL
comparison	NULL
,	NULL
IL-2	NULL
mRNA	NULL
was	NULL
included	NULL
.	NULL

Scanning	NULL
densitometry	NULL
data	NULL
are	NULL
shown	NULL
below	NULL
the	NULL
specific	NULL
mRNA	NULL
bands	NULL
and	NULL
were	NULL
obtained	NULL
by	NULL
dividing	NULL
all	NULL
values	NULL
by	NULL
the	NULL
corresponding	NULL
values	NULL
for	NULL
B-actin	NULL
mRNA	NULL
.	NULL

Control	NULL
cell	NULL
cultures	NULL
(	NULL
without	NULL
any	NULL
addition	NULL
of	NULL
drugs	NULL
)	NULL
were	NULL
set	NULL
to	NULL
100	NULL
arbitrary	NULL
units	NULL
for	NULL
the	NULL
different	NULL
mRNAs	NULL
.	NULL

Lane	NULL
numbers	NULL
are	NULL
indicated	NULL
at	NULL
the	NULL
bottom	NULL
.	NULL

Human	NULL
PBLs	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
(	NULL
4	NULL
mg/m	NULL
!	NULL
)	NULL

for	NULL
6	NULL
h	NULL
,	NULL
at	NULL
which	NULL
time	NULL
ciprofloxacin	NULL
(	NULL
80	NULL
pg/ml	NULL
!	NULL
)	NULL

and/or	NULL
actinomycin	NULL
D	NULL
(	NULL
Act	NULL
D	NULL
[	NULL
10	NULL
was	NULL
added	NULL
.	NULL

mRNAs	NULL
were	NULL
analyzed	NULL
at	NULL
0	NULL
,	NULL
2	NULL
,	NULL
and	NULL
4	NULL
h	NULL
of	NULL
additional	NULL
lymphocyte	NULL
incubation	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
including	NULL
different	NULL
blood	NULL
donors	NULL
.	NULL

(	NULL
genotoxic	NULL
stress	NULL
)	NULL
.	NULL

However	NULL
,	NULL
since	NULL
ciprofloxacin	NULL
did	NULL
not	NULL
increase	NULL
mutation	NULL
frequency	NULL
(	NULL
DNA	NULL
damage	NULL
)	NULL
in	NULL
a	NULL
shuttle	NULL
vector	NULL
plasmid	NULL
mutation	NULL
test	NULL
(	NULL
3	NULL
)	NULL
,	NULL
direct	NULL
interference	NULL
with	NULL
topoisomerase	NULL
II	NULL
might	NULL
be	NULL
another	NULL
mechanism	NULL
by	NULL
which	NULL
ciprofloxacin	NULL
induced	NULL
a	NULL
stress	NULL
response	NULL
.	NULL

Ciprofloxacin	NULL
at	NULL
high	NULL
concentrations	NULL
(	NULL
80	NULL
g/ml	NULL
)	NULL
has	NULL
in	NULL
fact	NULL
been	NULL
shown	NULL
to	NULL
interfere	NULL
with	NULL
topoisomerase	NULL
II	NULL
in	NULL
Raji	NULL
cells	NULL
when	NULL
investigated	NULL
by	NULL
a	NULL
neutral	NULL
elution	NULL
technique	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
topoisomerase	NULL
II	NULL
inhibitor	NULL
vepeside	NULL
(	NULL
VP-16	NULL
)	NULL
induces	NULL
vimentin	NULL
expression	NULL
and	NULL
activates	NULL
the	NULL
GADD153	NULL
promoter	NULL
in	NULL
the	NULL
monocytic	NULL
cell	NULL
line	NULL
U-937	NULL
(	NULL
20	NULL
,	NULL
31	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
vepeside	NULL
affects	NULL
protein	NULL
kinase	NULL
C	NULL
in	NULL
the	NULL
same	NULL
cell	NULL
line	NULL
,	NULL
causing	NULL
enhanced	NULL
AP-1	NULL
activity	NULL
,	NULL
but	NULL
without	NULL
influencing	NULL
NF-kB	NULL
binding	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
topoisomerase	NULL
II	NULL
in	NULL
thymocytes	NULL
by	NULL
teniposide	NULL
(	NULL
VM-26	NULL
)	NULL
leads	NULL
to	NULL
superinduction	NULL
of	NULL
c-jun	NULL
mRNA	NULL
expression	NULL
and	NULL
the	NULL
c-Jun	NULL
N-terminal	NULL
kinase	NULL
,	NULL
resulting	NULL
in	NULL
increased	NULL
AP-1	NULL
activity	NULL
(	NULL
39	NULL
)	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
that	NULL
teniposide	NULL
induces	NULL
the	NULL
transcription	NULL
of	NULL
heat	NULL
shock	NULL
genes	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
32	NULL
)	NULL
.	NULL

However	NULL
,	NULL
despite	NULL
the	NULL
fact	NULL
that	NULL
vepeside	NULL
has	NULL
been	NULL
thoroughly	NULL
documented	NULL
to	NULL
induce	NULL
genotoxic	NULL
stress	NULL
,	NULL
it	NULL
did	NULL
not	NULL
stimulate	NULL
IL-2	NULL
gene	NULL
expression	NULL
in	NULL
our	NULL
experimental	NULL
models	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
triggering	NULL
a	NULL
genotoxic	NULL
response	NULL
,	NULL
DNA-damaging	NULL
agents	NULL
may	NULL
directly	NULL
inhibit	NULL
topoisomerase	NULL
II	NULL
,	NULL
thus	NULL
facilitating	NULL
transcription	NULL
.	NULL

This	NULL
would	NULL
be	NULL
another	NULL
mecha-	NULL
ANTIMICROB	NULL
.	NULL

AGENTS	NULL
CHEMOTHER	NULL
.	NULL

nism	NULL
that	NULL
accounts	NULL
for	NULL
the	NULL
effects	NULL
seen	NULL
in	NULL
ciprofloxacin-treated	NULL
cells	NULL
.	NULL

DNA-damaging	NULL
agents	NULL
and	NULL
genotoxic	NULL
stress	NULL
may	NULL
also	NULL
increase	NULL
the	NULL
stability	NULL
of	NULL
certain	NULL
gene	NULL
transcripts	NULL
.	NULL

Recently	NULL
it	NULL
was	NULL
reported	NULL
that	NULL
photodynamic	NULL
treatment	NULL
of	NULL
HeLa	NULL
cells	NULL
resulted	NULL
in	NULL
the	NULL
prolonged	NULL
half-life	NULL
of	NULL
c-jun	NULL
and	NULL
c-fos	NULL
transcripts	NULL
(	NULL
18	NULL
)	NULL
.	NULL

UV	NULL
radiation	NULL
or	NULL
methylmethane	NULL
sulfonate	NULL
(	NULL
MMS	NULL
)	NULL
also	NULL
enhanced	NULL
mRNA	NULL
stability	NULL
for	NULL
the	NULL
growth	NULL
arrest	NULL
and	NULL
DNA	NULL
dam-age-inducible	NULL
(	NULL
gedd	NULL
)	NULL
genes	NULL
in	NULL
hamster	NULL
cells	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
untreated	NULL
exponentially	NULL
growing	NULL
cells	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
Mal-lardo	NULL
and	NULL
collaborators	NULL
described	NULL
an	NULL
extensive	NULL
IL-6	NULL
and	NULL
IL-1	NULL
mRNA	NULL
stabilization	NULL
in	NULL
human	NULL
monocytes	NULL
incubated	NULL
with	NULL
the	NULL
alkylating	NULL
agents	NULL
MMS	NULL
and	NULL
mitomycin	NULL
(	NULL
22	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
ciprofloxacin	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
increase	NULL
the	NULL
stability	NULL
of	NULL
immediate-early	NULL
mRNAs	NULL
:	NULL
no	NULL
difference	NULL
in	NULL
mRNA	NULL
turnover	NULL
was	NULL
detected	NULL
in	NULL
PBLs	NULL
incubated	NULL
with	NULL
or	NULL
without	NULL
ciprofloxacin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
transcriptional	NULL
inhibitor	NULL
actinomycin	NULL
D	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
results	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
number	NULL
of	NULL
genes	NULL
,	NULL
such	NULL
as	NULL
immediate-early	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
c-fos	NULL
and	NULL
c-jun	NULL
)	NULL
,	NULL
early	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
and	NULL
late-response	NULL
(	NULL
histone	NULL
H3	NULL
)	NULL
genes	NULL
(	NULL
4	NULL
)	NULL
.	NULL

In	NULL
cells	NULL
incubated	NULL
with	NULL
ciprofloxacin	NULL
,	NULL
a	NULL
time	NULL
relationship	NULL
appeared	NULL
to	NULL
exist	NULL
between	NULL
the	NULL
increased	NULL
c-fos	NULL
and	NULL
c-jun	NULL
mRNA	NULL
levels	NULL
on	NULL
one	NULL
hand	NULL
and	NULL
the	NULL
superinduced	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
mRNA	NULL
concentrations	NULL
on	NULL
the	NULL
other	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
5	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
ciprofloxacin-treated	NULL
Jurkat	NULL
cells	NULL
that	NULL
display	NULL
increased	NULL
AP-1	NULL
concentrations	NULL
at	NULL
15	NULL
min	NULL
(	NULL
30	NULL
)	NULL
,	NULL
any	NULL
upregulated	NULL
AP-1	NULL
binding	NULL
by	NULL
ciprofloxacin	NULL
was	NULL
not	NULL
detected	NULL
at	NULL
earlier	NULL
time	NULL
points	NULL
than	NULL
2	NULL
h	NULL
in	NULL
primary	NULL
lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
PBLs	NULL
,	NULL
the	NULL
upregulated	NULL
expression	NULL
of	NULL
c-fos	NULL
and	NULL
c-jun	NULL
mRNAs	NULL
was	NULL
not	NULL
preceded	NULL
by	NULL
increased	NULL
AP-1	NULL
activity	NULL
.	NULL

The	NULL
mRNAs	NULL
of	NULL
at	NULL
least	NULL
six	NULL
different	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
included	NULL
in	NULL
the	NULL
AP-1	NULL
protein	NULL
complex	NULL
are	NULL
detected	NULL
in	NULL
stimulated	NULL
T	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
our	NULL
highly	NULL
purified	NULL
CD4*	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
,	NULL
the	NULL
induced	NULL
AP-1	NULL
detected	NULL
at	NULL
2	NULL
and	NULL
3	NULL
h	NULL
of	NULL
activation	NULL
mainly	NULL
consisted	NULL
of	NULL
the	NULL
proteins	NULL
FosB	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
JunD	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
immediate-early	NULL
genes	NULL
encoding	NULL
members	NULL
of	NULL
the	NULL
Jun	NULL
and	NULL
Fos	NULL
families	NULL
are	NULL
tightly	NULL
controlled	NULL
by	NULL
transcription	NULL
factors	NULL
other	NULL
than	NULL
AP-1	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
c-fos	NULL
is	NULL
mediated	NULL
by	NULL
factors	NULL
binding	NULL
to	NULL
a	NULL
cyclic	NULL
AMP	NULL
-responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
,	NULL
Sis-inducible	NULL
enhancer	NULL
(	NULL
SIE	NULL
)	NULL
,	NULL
and	NULL
,	NULL
finally	NULL
,	NULL
a	NULL
serum-response	NULL
element	NULL
(	NULL
SRE	NULL
)	NULL
(	NULL
see	NULL
reference	NULL
16	NULL
for	NULL
a	NULL
review	NULL
)	NULL
.	NULL

Numerous	NULL
transcriptional	NULL
regulation	NULL
factors	NULL
,	NULL
including	NULL
CRE-binding	NULL
proteins	NULL
and	NULL
the	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
factors	NULL
,	NULL
including	NULL
CRE-binding	NULL
proteins	NULL
and	NULL
the	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
group	NULL
,	NULL
bind	NULL
to	NULL
the	NULL
c-fos	NULL
enhancer	NULL
and	NULL
promoter	NULL
region	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
c-jun	NULL
is	NULL
induced	NULL
via	NULL
a	NULL
tetrade-canoyl	NULL
phorbol	NULL
acetate-responsive	NULL
element	NULL
(	NULL
TRE	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
proposed	NULL
to	NULL
be	NULL
recognized	NULL
by	NULL
c-Jun-activating	NULL
transcription	NULL
factor	NULL
2	NULL
(	NULL
ATF2	NULL
)	NULL
heterodimers	NULL
in	NULL
addition	NULL
to	NULL
other	NULL
presently	NULL
unknown	NULL
factors	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
ciprofloxacin	NULL
induced	NULL
transcripts	NULL
consisting	NULL
of	NULL
members	NULL
of	NULL
the	NULL
Jun	NULL
and	NULL
Fos	NULL
families	NULL
,	NULL
resulting	NULL
in	NULL
dimeric	NULL
protein	NULL
complexes	NULL
that	NULL
in	NULL
turn	NULL
constituted	NULL
AP-1	NULL
.	NULL

Depending	NULL
on	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
AP-1	NULL
dimer	NULL
,	NULL
different	NULL
sequence	NULL
elements	NULL
are	NULL
preferentially	NULL
recognized	NULL
.	NULL

Two	NULL
AP-1	NULL
binding	NULL
sequences	NULL
exist	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
T-cell	NULL
cytokine	NULL
IL-2	NULL
(	NULL
4	NULL
,	NULL
6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
a	NULL
less	NULL
important	NULL
distal	NULL
AP-1	NULL
site	NULL
,	NULL
the	NULL
proximal	NULL
AP-1	NULL
sequence	NULL
is	NULL
crucial	NULL
for	NULL
IL-2	NULL
gene	NULL
induction	NULL
and	NULL
represents	NULL
a	NULL
major	NULL
site	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
responsiveness	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
proximal	NULL
site	NULL
diminishes	NULL
the	NULL
IL-2	NULL
promoter	NULL
activity	NULL
by	NULL
approximately	NULL
75	NULL
%	NULL
,	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
(	NULL
6	NULL
)	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
ciprofloxacin	NULL
on	NULL
IL-2	NULL
promoter	NULL
induction	NULL
in	NULL
a	NULL
well-defined	NULL
murine	NULL
system	NULL
by	NULL
using	NULL
different	NULL
constructs	NULL
consisting	NULL
of	NULL
mutated	NULL
IL-2	NULL
enhancer	NULL
and	NULL
promoter	NULL
regions	NULL
(	NULL
27	NULL
)	NULL
.	NULL

No	NULL
upregulated	NULL
CAT	NULL
conversion	NULL
was	NULL
voL	NULL
.	NULL

42	NULL
,	NULL
1998	NULL
found	NULL
with	NULL
an	NULL
IL-2	NULL
promoter	NULL
construct	NULL
lacking	NULL
the	NULL
proximal	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ciprofloxacin	NULL
(	NULL
25a	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
experiments	NULL
with	NULL
IL-2	NULL
promoter	NULL
constructs	NULL
lacking	NULL
the	NULL
NFAT-1	NULL
or	NULL
binding	NULL
sequences	NULL
,	NULL
ciprofloxacin	NULL
increased	NULL
CAT	NULL
activity	NULL
regardless	NULL
of	NULL
the	NULL
mutated	NULL
sequence	NULL
compared	NULL
to	NULL
that	NULL
in	NULL
drug-free	NULL
controls	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
the	NULL
present	NULL
study	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
ciprofloxacin	NULL
increased	NULL
expression	NULL
for	NULL
both	NULL
constructs	NULL
MT-CAT-SV	NULL
and	NULL
IL-2-CAT-SV	NULL
containing	NULL
the	NULL
promoters	NULL
metallothionein	NULL
and	NULL
IL-2	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

To	NULL
reach	NULL
the	NULL
detection	NULL
limit	NULL
for	NULL
CAT	NULL
in	NULL
primary	NULL
lymphocytes	NULL
,	NULL
we	NULL
had	NULL
to	NULL
include	NULL
the	NULL
SV40	NULL
enhancer	NULL
.	NULL

It	NULL
is	NULL
well	NULL
known	NULL
that	NULL
AP-1	NULL
is	NULL
crucial	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
SV40	NULL
enhancer	NULL
and	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
6	NULL
,	NULL
25	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
AP-1	NULL
seems	NULL
to	NULL
be	NULL
less	NULL
important	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
metallothioneins	NULL
(	NULL
24	NULL
)	NULL
.	NULL

When	NULL
the	NULL
AP-1	NULL
site	NULL
was	NULL
mutated	NULL
in	NULL
the	NULL
human	NULL
metallothionein	NULL
promoter	NULL
,	NULL
the	NULL
low	NULL
basal	NULL
activity	NULL
disappeared	NULL
,	NULL
while	NULL
the	NULL
metallothionein	NULL
gene	NULL
still	NULL
could	NULL
be	NULL
induced	NULL
by	NULL
Zn**	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Unpublished	NULL
observations	NULL
from	NULL
our	NULL
laboratory	NULL
reveal	NULL
that	NULL
in	NULL
contrast	NULL
to	NULL
an	NULL
intact	NULL
promoter	NULL
,	NULL
the	NULL
metallothionein	NULL
promoter	NULL
with	NULL
a	NULL
mutated	NULL
AP-1	NULL
site	NULL
(	NULL
21	NULL
)	NULL
was	NULL
not	NULL
enhanced	NULL
by	NULL
ciprofloxacin	NULL
in	NULL
stimulated	NULL
murine	NULL
EL-4	NULL
cells	NULL
.	NULL

Most	NULL
likely	NULL
the	NULL
ciprofloxacin-dependent	NULL
upregulation	NULL
of	NULL
MT-CAT-SV	NULL
activity	NULL
in	NULL
PBLs	NULL
was	NULL
not	NULL
caused	NULL
by	NULL
the	NULL
non-AP-1-related	NULL
transcription	NULL
factors	NULL
(	NULL
24	NULL
)	NULL
but	NULL
was	NULL
due	NULL
to	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
sequences	NULL
in	NULL
the	NULL
metallothionein	NULL
promoter	NULL
and	NULL
the	NULL
SV40	NULL
enhancer	NULL
element	NULL
.	NULL

Ciprofloxacin	NULL
appeared	NULL
to	NULL
mainly	NULL
interfere	NULL
with	NULL
AP-1	NULL
activity	NULL
when	NULL
transcriptional	NULL
activity	NULL
was	NULL
examined	NULL
with	NULL
CAT	NULL
con-structs	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
an	NULL
association	NULL
between	NULL
stress	NULL
response	NULL
and	NULL
cytokine	NULL
superinduction	NULL
triggered	NULL
by	NULL
ciprofloxacin	NULL
has	NULL
been	NULL
described	NULL
in	NULL
the	NULL
present	NULL
communication	NULL
.	NULL

Several	NULL
gene	NULL
transcripts	NULL
included	NULL
in	NULL
the	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
families	NULL
in	NULL
addition	NULL
to	NULL
most	NULL
T-cell	NULL
cytokines	NULL
(	NULL
30	NULL
)	NULL
were	NULL
augmented	NULL
in	NULL
primary	NULL
lymphocytes	NULL
exposed	NULL
to	NULL
ciprofloxacin	NULL
.	NULL

Moreover	NULL
,	NULL
AP-1	NULL
binding	NULL
activity	NULL
was	NULL
increased	NULL
in	NULL
ciprofloxacin-treated	NULL
PBLs	NULL
,	NULL
which	NULL
is	NULL
a	NULL
commonly	NULL
described	NULL
phenomenon	NULL
during	NULL
mammalian	NULL
stress	NULL
.	NULL

Despite	NULL
the	NULL
available	NULL
evidence	NULL
of	NULL
immunomodulatory	NULL
effects	NULL
of	NULL
ciprofloxacin	NULL
in	NULL
vivo	NULL
(	NULL
36	NULL
,	NULL
41	NULL
)	NULL
,	NULL
the	NULL
clinical	NULL
significance	NULL
of	NULL
our	NULL
findings	NULL
warrants	NULL
further	NULL
studies	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Michael	NULL
Karin	NULL
,	NULL
Carsten	NULL
Jonat	NULL
,	NULL
and	NULL
Tullia	NULL
Lindsten	NULL
for	NULL
providing	NULL
us	NULL
with	NULL
plasmids	NULL
.	NULL

This	NULL
investigation	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Anna	NULL
and	NULL
Edwin	NULL
Berger	NULL
Foundation	NULL
,	NULL
the	NULL
Greta	NULL
and	NULL
Johan	NULL
Kock	NULL
Foundation	NULL
,	NULL
the	NULL
Cancer	NULL
Foundation	NULL
at	NULL
University	NULL
Hospital	NULL
MAS	NULL
,	NULL
the	NULL
Swedish	NULL
Medical	NULL
Research	NULL
Council	NULL
,	NULL
and	NULL
the	NULL
Osterlund	NULL
Foundation	NULL
.	NULL

REFERENCES	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
X.	NULL
Mao	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
C.-Y	NULL
.	NULL

Wang	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
R.	NULL
Bravo	NULL
,	NULL
K.	NULL
Kovary	NULL
,	NULL
J.	NULL
M.	NULL
Leiden	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
NFAT-1	NULL
DNA	NULL
binding	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
contains	NULL
Fra-1	NULL
and	NULL
JunB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1911-1919	NULL
.	NULL

2	NULL
.	NULL

Bredberg	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Brant	NULL
,	NULL
and	NULL
M.	NULL
Jaszyk	NULL
.	NULL

1991	NULL
.	NULL

Ciprofloxacin-induced	NULL
inhibition	NULL
of	NULL
topoisomerase	NULL
II	NULL
in	NULL
human	NULL
lymphoblastoid	NULL
cells	NULL
.	NULL

Antimicrob	NULL
.	NULL

Agents	NULL
Chemother	NULL
.	NULL

35:448-450	NULL
.	NULL

3	NULL
.	NULL

Bredberg	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Brant	NULL
,	NULL
K.	NULL
Riesbeck	NULL
,	NULL
Y.	NULL
Azou	NULL
,	NULL
and	NULL
A.	NULL
Forsgren	NULL
.	NULL

1989	NULL
.	NULL

4-Quinolone	NULL
antibiotics	NULL
:	NULL
positive	NULL
genotoxic	NULL
screening	NULL
tests	NULL
despite	NULL
an	NULL
apparent	NULL
lack	NULL
of	NULL
mutation	NULL
induction	NULL
.	NULL

Mutat	NULL
.	NULL

Res	NULL
.	NULL

211:171-181	NULL
.	NULL

4	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Clipstone	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transmission	NULL
between	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
the	NULL
nucleus	NULL
of	NULL
T-lymphocytes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63:1045-1083	NULL
.	NULL

5	NULL
.	NULL

Drlica	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
X.	NULL
Zhao	NULL
.	NULL

1997	NULL
.	NULL

DNA	NULL
gyrase	NULL
,	NULL
topoisomerase	NULL
IV	NULL
,	NULL
and	NULL
the	NULL
4-quinolones	NULL
.	NULL

Microbiol	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Rev	NULL
.	NULL

61:377-392	NULL
.	NULL

6	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
J.-P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Balagaje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715-1724	NULL
.	NULL

7	NULL
.	NULL

Engelberg	NULL
,	NULL
D.	NULL
,	NULL
C.	NULL
Klein	NULL
,	NULL
H.	NULL
Martinetto	NULL
,	NULL
K.	NULL
Struhl	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
UV	NULL
response	NULL
involving	NULL
the	NULL
Ras	NULL
signaling	NULL
pathway	NULL
and	NULL
AP-1	NULL
transcription	NULL
factors	NULL
is	NULL
conserved	NULL
between	NULL
yeast	NULL
and	NULL
mammals	NULL
.	NULL

Cell	NULL
77:381-390	NULL
.	NULL

CIPROFLOXACIN	NULL
AND	NULL
MAMMALIAN	NULL
STRESS	NULL
RESPONSE	NULL
-	NULL
1929	NULL
8	NULL
.	NULL

Forsgren	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
F.	NULL
Schlossman	NULL
,	NULL
and	NULL
T.	NULL
F.	NULL
Tedder	NULL
.	NULL

1987	NULL
.	NULL

4-Quinolone	NULL
drugs	NULL
affect	NULL
cell	NULL
cycle	NULL
progression	NULL
and	NULL
function	NULL
of	NULL
human	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
.	NULL

Antimicrob	NULL
.	NULL

Agents	NULL
.	NULL

Chemother	NULL
.	NULL

31:768-773.	NULL
.	NULL

Hattori	NULL
,	NULL
K.	NULL
,	NULL
P.	NULL
Angel	NULL
,	NULL
M.	NULL
M.	NULL
LeBeau	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1988	NULL
.	NULL

Structure	NULL
and	NULL
chromosomal	NULL
localization	NULL
of	NULL
the	NULL
functional	NULL
intronless	NULL
human	NULL
protooncogene	NULL
JUN	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:9148-9152	NULL
.	NULL

10	NULL
.	NULL

Herrlich	NULL
,	NULL
P.	NULL
,	NULL
H.	NULL
Ponta	NULL
,	NULL
and	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
.	NULL

1992	NULL
.	NULL

DNA	NULL
damage-induced	NULL
gene	NULL
expression	NULL
:	NULL
signal	NULL
transduction	NULL
and	NULL
relation	NULL
to	NULL
growth	NULL
factor	NULL
signaling	NULL
.	NULL

Rev	NULL
.	NULL

Physiol	NULL
.	NULL

Biochem	NULL
.	NULL

Pharmacol	NULL
.	NULL

119:187-223	NULL
.	NULL

11	NULL
.	NULL

Holbrook	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Y.	NULL
Liu	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Fornace	NULL
,	NULL
Jr.	NULL
1996	NULL
.	NULL

Signaling	NULL
events	NULL
controlling	NULL
the	NULL
molecular	NULL
response	NULL
to	NULL
genotoxic	NULL
stress	NULL
,	NULL
p.	NULL
273-288	NULL
.	NULL

In	NULL
U.	NULL
Feige	NULL
,	NULL
R.	NULL
I.	NULL
Morimoto	NULL
,	NULL
I.	NULL
Yahara	NULL
,	NULL
and	NULL
B.	NULL
Polla	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Stress-inducible	NULL
cellular	NULL
responses-1996	NULL
.	NULL

Birkhd	NULL
@	NULL
user	NULL
Verlag	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
.	NULL

12	NULL
.	NULL

Jackman	NULL
,	NULL
J.	NULL
,	NULL
L	NULL
Alamo	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Fornace	NULL
,	NULL
Jr.	NULL
1994	NULL
.	NULL

Genotoxic	NULL
stress	NULL
confers	NULL
preferential	NULL
and	NULL
coordinate	NULL
messenger	NULL
RNA	NULL
stability	NULL
on	NULL
the	NULL
five	NULL
gadd	NULL
genes	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

54:5656-5662	NULL
.	NULL

13	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
V.	NULL
E.	NULL
Valge-Archer	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:1240-1250	NULL
.	NULL

14	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
V.	NULL
E.	NULL
Valge-Archer	NULL
,	NULL
A.	NULL
J.	NULL
Sinskey	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
AP-1	NULL
site	NULL
at	NULL
-150	NULL
bp	NULL
,	NULL
but	NULL
not	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
,	NULL
is	NULL
likely	NULL
to	NULL
represent	NULL
the	NULL
major	NULL
target	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
in	NULL
the	NULL
interleukin	NULL
2	NULL
promoter	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:853-862	NULL
.	NULL

15	NULL
.	NULL

Kiigi	NULL
,	NULL
J.	NULL
H.	NULL
1991	NULL
.	NULL

Overview	NULL
of	NULL
metallothionein	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

205:613-626	NULL
.	NULL

16	NULL
.	NULL

Karin	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Zheng-Gang	NULL
,	NULL
and	NULL
E.	NULL
Zandi	NULL
.	NULL

1997	NULL
.	NULL

AP-1	NULL
function	NULL
and	NULL
regula-tion	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

9240-246	NULL
.	NULL

17	NULL
.	NULL

Kharabanda	NULL
,	NULL
S.	NULL
,	NULL
Z.-M.	NULL
Yuan	NULL
,	NULL
R.	NULL
Weichselbaum	NULL
,	NULL
and	NULL
D.	NULL
Kufe	NULL
.	NULL

1997	NULL
.	NULL

Functional	NULL
role	NULL
for	NULL
the	NULL
c-Abl	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
in	NULL
the	NULL
cellular	NULL
response	NULL
to	NULL
genotoxic	NULL
stress	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1333:01-O7	NULL
.	NULL

18	NULL
.	NULL

Kick	NULL
,	NULL
G.	NULL
,	NULL
G.	NULL
Messer	NULL
,	NULL
G.	NULL
Plewig	NULL
,	NULL
P.	NULL
Kind	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Goetz	NULL
.	NULL

1996	NULL
.	NULL

Strong	NULL
and	NULL
prolonged	NULL
induction	NULL
of	NULL
c-jun	NULL
and	NULL
c-fos	NULL
proto-oncogenes	NULL
by	NULL
photodynamic	NULL
therapy	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
74:30-36	NULL
.	NULL

19	NULL
.	NULL

Kletter	NULL
,	NULL
Y.	NULL
,	NULL
I.	NULL
Riklis	NULL
,	NULL
I	NULL
Shalit	NULL
,	NULL
and	NULL
I.	NULL
Fabian	NULL
.	NULL

1991	NULL
.	NULL

Enhanced	NULL
repopulation	NULL
of	NULL
murine	NULL
hematopoietic	NULL
organs	NULL
in	NULL
sublethally	NULL
irradiated	NULL
mice	NULL
after	NULL
treatment	NULL
with	NULL
ciprofloxacin	NULL
.	NULL

Blood	NULL
78:1685-1691	NULL
.	NULL

20	NULL
.	NULL

Luethy	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
N.	NULL
J.	NULL
Holbrook	NULL
.	NULL

1992	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
gedd153	NULL
promoter	NULL
by	NULL
genotoxic	NULL
agents	NULL
:	NULL
a	NULL
rapid	NULL
specific	NULL
response	NULL
to	NULL
DNA	NULL
damage	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

52:5-10	NULL
.	NULL

21	NULL
.	NULL

Makarov	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
C.	NULL
Jonat	NULL
,	NULL
and	NULL
S.	NULL
Haskill	NULL
.	NULL

1994	NULL
.	NULL

Hyperinducible	NULL
human	NULL
metallothionein	NULL
promoter	NULL
with	NULL
a	NULL
low	NULL
level	NULL
basal	NULL
activity	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

22:1504-1505	NULL
.	NULL

22	NULL
.	NULL

Mallardo	NULL
,	NULL
M.	NULL
,	NULL
V.	NULL
Giordano	NULL
,	NULL
E.	NULL
Dragonetti	NULL
,	NULL
G.	NULL
Scala	NULL
,	NULL
and	NULL
I.	NULL
Quinto	NULL
.	NULL

1994	NULL
.	NULL

DNA	NULL
damaging	NULL
agents	NULL
increase	NULL
the	NULL
stability	NULL
of	NULL
interleukin-1	NULL
alpha	NULL
,	NULL
interleukin-1	NULL
beta	NULL
,	NULL
and	NULL
interleukin-6	NULL
transcripts	NULL
and	NULL
the	NULL
production	NULL
of	NULL
the	NULL
relative	NULL
proteins	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:14899-14904	NULL
.	NULL

23	NULL
.	NULL

Perez	NULL
,	NULL
C.	NULL
,	NULL
N.	NULL
E.	NULL
Vilaboa	NULL
,	NULL
L.	NULL
Garcia-Bermejo	NULL
,	NULL
E.	NULL
de-Blas	NULL
,	NULL
A.	NULL
M.	NULL
Creighton	NULL
,	NULL
and	NULL
P.	NULL
Aller	NULL
.	NULL

1997	NULL
.	NULL

Differentiation	NULL
of	NULL
U-937	NULL
promonocytic	NULL
cells	NULL
by	NULL
etoposide	NULL
and	NULL
ICRF-193	NULL
,	NULL
two	NULL
antitumour	NULL
DNA	NULL
topoisomerase	NULL
inhibitors	NULL
with	NULL
different	NULL
mechanisms	NULL
of	NULL
action	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Sci	NULL
.	NULL

110:337-343	NULL
.	NULL

24	NULL
.	NULL

Radtke	NULL
,	NULL
F.	NULL
,	NULL
R.	NULL
Heuchel	NULL
,	NULL
O.	NULL
Georgiev	NULL
,	NULL
M.	NULL
Hergersberg	NULL
,	NULL
M.	NULL
Gariglio	NULL
,	NULL
Z.	NULL
Dem-bic	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1993	NULL
.	NULL

Cloned	NULL
transcription	NULL
factor	NULL
MTF-1	NULL
activates	NULL
the	NULL
mouse	NULL
metallothionein	NULL
I	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:1355-1362	NULL
.	NULL

25	NULL
.	NULL

Rahmsdorf	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
and	NULL
P.	NULL
Herrlich	NULL
.	NULL

1990	NULL
.	NULL

Regulation	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
tumor	NULL
promoters	NULL
.	NULL

Pharmacol	NULL
.	NULL

Ther	NULL
.	NULL

48:157-188	NULL
.	NULL

25a.Riesbeck	NULL
,	NULL
K.	NULL
Unpublished	NULL
observations	NULL
.	NULL

26	NULL
.	NULL

Riesbeck	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
Andersson	NULL
,	NULL
M.	NULL
Gullberg	NULL
,	NULL
and	NULL
A.	NULL
Forsgren	NULL
.	NULL

1989	NULL
.	NULL

Fluorinated	NULL
4-quinolones	NULL
induce	NULL
hyperproduction	NULL
of	NULL
interleukin	NULL
2	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2809-2813	NULL
.	NULL

27	NULL
.	NULL

Riesbeck	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
A.	NULL
Forsgren	NULL
.	NULL

1994	NULL
.	NULL

Increased	NULL
interleukin	NULL
2	NULL
transcription	NULL
in	NULL
murine	NULL
lymphocytes	NULL
by	NULL
ciprofloxacin	NULL
.	NULL

Immunopharmacology	NULL
27:155-164	NULL
.	NULL

28	NULL
.	NULL

Riesbeck	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
A.	NULL
Forsgren	NULL
.	NULL

1995	NULL
.	NULL

CP-115,953	NULL
stimulates	NULL
cytokine	NULL
production	NULL
by	NULL
lymphocytes	NULL
.	NULL

Antimicrob	NULL
.	NULL

Agents	NULL
Chemother	NULL
.	NULL

39:476-483	NULL
.	NULL

29	NULL
.	NULL

Riesbeck	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Gullberg	NULL
,	NULL
and	NULL
A.	NULL
Forsgren	NULL
.	NULL

1994	NULL
.	NULL

Evidence	NULL
that	NULL
the	NULL
antibiotic	NULL
ciprofloxacin	NULL
counteracts	NULL
cyclosporine-dependent	NULL
suppression	NULL
of	NULL
cytokine	NULL
production	NULL
.	NULL

Transplantation	NULL
57:267-272	NULL
.	NULL

30	NULL
.	NULL

Riesbeck	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Sigvardsson	NULL
,	NULL
T.	NULL
Leanderson	NULL
,	NULL
and	NULL
A.	NULL
Forsgren	NULL
.	NULL

1994	NULL
.	NULL

Superinduction	NULL
of	NULL
cytokine	NULL
gene	NULL
transcription	NULL
by	NULL
ciprofloxacin	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:343-352	NULL
.	NULL

31	NULL
.	NULL

Rius	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
R.	NULL
Zorilla	NULL
,	NULL
C.	NULL
Cabans	NULL
,	NULL
F.	NULL
Mata	NULL
,	NULL
C.	NULL
Bernabeu	NULL
,	NULL
and	NULL
P.	NULL
Aller	NULL
.	NULL

1991	NULL
.	NULL

Differentiation	NULL
of	NULL
human	NULL
promonocytic	NULL
leukemia	NULL
U-937	NULL
cells	NULL
with	NULL
DNA	NULL
topoisomerase	NULL
II	NULL
inhibitors	NULL
:	NULL
induction	NULL
of	NULL
vimentin	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

39:442-448	NULL
.	NULL

32	NULL
.	NULL

Schaak	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
Schedl	NULL
,	NULL
and	NULL
T.	NULL
Schenk	NULL
.	NULL

1990	NULL
.	NULL

Transcription	NULL
of	NULL
adenovirus	NULL
and	NULL
HeLa	NULL
cell	NULL
genes	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
drugs	NULL
that	NULL
inhibit	NULL
topoisomerase	NULL
I	NULL
and	NULL
II	NULL
function	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18:1499-1508	NULL
.	NULL

33	NULL
.	NULL

Scholer	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
A.	NULL
K.	NULL
Hatzopoulos	NULL
,	NULL
R.	NULL
Balling	NULL
,	NULL
N.	NULL
Suzuki	NULL
,	NULL
and	NULL
P.	NULL
Gruss	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
family	NULL
of	NULL
octamer-specific	NULL
proteins	NULL
present	NULL
during	NULL
mouse	NULL
embryogenesis	NULL
:	NULL
evidence	NULL
for	NULL
germline-specific	NULL
expression	NULL
of	NULL
an	NULL
Oct	NULL
factor	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:2543-2550	NULL
.	NULL

34	NULL
.	NULL

Schultze-Osthoff	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
K.	NULL
A.	NULL
Bauer	NULL
,	NULL
M.	NULL
Vogt	NULL
,	NULL
and	NULL
S.	NULL
Wesselborg	NULL
.	NULL

1997	NULL
.	NULL

Oxidative	NULL
stress	NULL
and	NULL
signal	NULL
transduction	NULL
.	NULL

Int	NULL
.	NULL

J.	NULL
Vitam	NULL
.	NULL

Nutr	NULL
.	NULL

Res	NULL
.	NULL

67:336-342	NULL
.	NULL

35	NULL
.	NULL

Schwartz	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
J.	NULL
S.	NULL
Lazo	NULL
,	NULL
J.	NULL
C.	NULL
Yalowich	NULL
,	NULL
I.	NULL
Reynolds	NULL
,	NULL
V.	NULL
E.	NULL
Kagan	NULL
,	NULL
V.	NULL
\o	NULL
1930	NULL
36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

RIESBECK	NULL
ET	NULL
AL	NULL
.	NULL

Tyurin	NULL
,	NULL
Y.-M.	NULL
Kim	NULL
,	NULL
S.	NULL
C.	NULL
Watkins	NULL
,	NULL
and	NULL
B.	NULL
R.	NULL
Pitt	NULL
.	NULL

1994	NULL
.	NULL

Cytoplasmic	NULL
metallothioncin	NULL
overexpression	NULL
protects	NULL
NIH	NULL
3T3	NULL
cells	NULL
from	NULL
tert-butyl	NULL
hydroper-oxide	NULL
toxicity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:15238-15243	NULL
.	NULL

Shalit	NULL
,	NULL
L.	NULL
,	NULL
Y.	NULL
Kletter	NULL
,	NULL
K.	NULL
Weiss	NULL
,	NULL
T.	NULL
Gruss	NULL
,	NULL
and	NULL
I.	NULL
Fabian	NULL
.	NULL

1997	NULL
.	NULL

Enhanced	NULL
hematopoiesis	NULL
in	NULL
sublethally	NULL
irradiated	NULL
mice	NULL
treated	NULL
with	NULL
various	NULL
quinolones	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Haematol	NULL
.	NULL

58:92-98	NULL
.	NULL

Smith	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Fornace	NULL
,	NULL
Jr.	NULL
1996	NULL
.	NULL

Mammalian	NULL
DNA	NULL
damage-inducible	NULL
genes	NULL
associated	NULL
with	NULL
growth	NULL
arrest	NULL
and	NULL
apoptosis	NULL
.	NULL

Mutat	NULL
.	NULL

Res	NULL
.	NULL

340:109-124	NULL
.	NULL

Stiinkel	NULL
,	NULL
K.	NULL
G.	NULL
E.	NULL
,	NULL
G.	NULL
Hewlett	NULL
,	NULL
and	NULL
H.	NULL
J.	NULL
Zeiler	NULL
.	NULL

1991	NULL
.	NULL

Ciprofloxacin	NULL
enhances	NULL
T	NULL
cell	NULL
function	NULL
by	NULL
modulating	NULL
interleukin	NULL
activities	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

86:525-531	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

ANTIMICROB	NULL
.	NULL

AGENTS	NULL
CHEMOTHER	NULL
.	NULL

Testolin	NULL
,	NULL
L.	NULL
,	NULL
C.	NULL
Carson	NULL
,	NULL
Y.	NULL
Wang	NULL
,	NULL
P.	NULL
R.	NULL
Walker	NULL
,	NULL
U.	NULL
Armato	NULL
,	NULL
and	NULL
M.	NULL
Sikorska	NULL
.	NULL

1997	NULL
.	NULL

Jun	NULL
and	NULL
JNK	NULL
kinase	NULL
are	NULL
activated	NULL
in	NULL
thymocytes	NULL
in	NULL
response	NULL
to	NULL
VM26	NULL
and	NULL
radiation	NULL
but	NULL
not	NULL
glucocorticoids	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

230:220-232	NULL
.	NULL

Walker	NULL
,	NULL
G.	NULL
C.	NULL
1984	NULL
.	NULL

Mutagenesis	NULL
and	NULL
inducible	NULL
responses	NULL
to	NULL
deoxyribonu-cleic	NULL
acid	NULL
damage	NULL
in	NULL
Escherichia	NULL
coli	NULL
.	NULL

Microbiol	NULL
.	NULL

Rev	NULL
.	NULL

48:60-93	NULL
.	NULL

Wrishko	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
M.	NULL
Levine	NULL
,	NULL
D.	NULL
R.	NULL
N.	NULL
Primmett	NULL
,	NULL
S.	NULL
Kim	NULL
,	NULL
N.	NULL
Partovi	NULL
,	NULL
S.	NULL
Lewis	NULL
,	NULL
D.	NULL
Landsberg	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Keown	NULL
.	NULL

1997	NULL
.	NULL

Investigation	NULL
of	NULL
a	NULL
possible	NULL
interaction	NULL
between	NULL
ciprofloxacin	NULL
and	NULL
cyclosporine	NULL
in	NULL
renal	NULL
transplant	NULL
patients	NULL
.	NULL

Transplantation	NULL
64:996-999	NULL
.	NULL

Zebavi-Willner	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
I.	NULL
Shalit	NULL
.	NULL

1989	NULL
.	NULL

Enhancement	NULL
of	NULL
interleukin-2	NULL
production	NULL
in	NULL
human	NULL
lymphocytes	NULL
by	NULL
two	NULL
new	NULL
quinolone	NULL
derivatives	NULL
.	NULL

Lympho-kine	NULL
Res	NULL
.	NULL

3135-46	NULL
.	NULL

